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Gary Marshall Long 
BEET-ING MUSCLE DYSFUNCTION AND EXERCISE INTOLERANCE IN 
PULMONARY HYPERTENSION 
Background: Pulmonary Hypertension (PH) is a devastating disease characterized 
by pulmonary arterial remodeling, right ventricular dysfunction and ultimately right heart 
failure. Increased emphasis has been given to skeletal muscle dysfunction in PH, and to 
its implication in the severe exercise intolerance that is a hallmark of the condition. In 
this dissertation, skeletal muscle blood flow was measured via the microsphere technique 
at rest and during exercise (Aim 1), with an acute dose of dietary nitrate via beetroot juice 
(BRJ) gavage used to determine if supplementation could improve muscle blood flow and 
alter energetics (Aim 2). VO2max, voluntary running and grip strength tests were used to 
determine the effect of disease on performance, and to test for an ergogenic effect of BRJ 
vs. placebo (PL) in healthy and PH rats (Aim 3). Methods: A prospective, randomized, 
counterbalanced, placebo-controlled trial was used to examine the aforementioned aims 
across four groups; PH rats (induced with monocrotaline, MCT, 60mg/kg, s.q., 4 weeks) 
supplemented with BRJ (MCT BRJ, n=9); PH rats supplemented with placebo (MCT PL, 
n=9); healthy control rats (vehicle, s.q.) supplemented with BRJ (CON BRJ, n=8); 
healthy control rats supplemented with placebo (CON PL, n=9). Results: Monocrotaline 
induced a severe PH phenotype evidenced by increased RV wall thickness, RV 
hypertrophy, RVSP and reduced cardiac output and stroke volume compared to controls 
(p=<0.001). MCT rats demonstrated lower muscle blood flow at rest, and more 
prominently during exercise compared to controls (p=0.007-0.047), regardless of 
supplementation. MCT rats displayed a greater reliance on anaerobic metabolism, 
vii 
demonstrated by increased blood lactate accumulation (p=<0.001), and this was 
significantly related to reduced blood flow during exercise (r=-0.5879, p=0.001). BRJ 
supplementation resulted in increased plasma nitrate and nitrite compared to PL 
(p=<0.001), but at the skeletal muscle level, only nitrate was increased after BRJ. BRJ 
did not have a significant effect on blood flow, with no improvement during exercise 
shown vs. PL. Similarly, BRJ did not significantly improve exercise function in MCT or 
CON rats. Conclusion: MCT rats demonstrated a reduction in muscle blood flow, with 
BRJ supplementation not resulting in improved flow or exercise performance.  
 
Andrew R. Coggan, Ph.D., Chair 
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Chapter One: Introduction to the Study 
Introduction 
Pulmonary Hypertension (PH) is a complex, progressive and devastating disease 
characterized by pulmonary vascular remodeling, right ventricular hypertrophy, skeletal 
muscle dysfunction and ultimately right heart failure (Elliot & Kiely, 2004). Defined 
clinically as a right ventricular systolic mean arterial pressure of >25mmHg, this broad 
disorder was first classified in 1973 by the World Health Organization (Kiely, Elliot, 
Sabroe, & Condliffe, 2013). In the subsequent years, advancing knowledge of PH 
etiologies has led to a refined understanding of the disease, now classified according to 
pathological characteristics and therapeutic approaches (Simonneau et al., 2014). Table 
1.1 summarizes the most recent classification of PH, outlining the five groups of 
disorders that are now widely accepted and adopted by experts worldwide.  
 
Group Type Associations 
I Pulmonary Arterial 
Hypertension (PAH) 
• Idiopathic   
• Heritable 
• Drug and toxin induced  
• Associated (HIV, portal HTN, 
congenital heart disease, 
schistosomiasis) 
II PH with left heart disease • Systolic/diastolic dysfunction 
• Valvular disease 
• Cardiomyopathies 
III PH due to lung disease/hypoxia • COPD 
• Sleep disorder  
• Exposure to high altitude 
IV Chronic thromboembolic PH 
(CTEPH) 
• From chronic pulmonary embolism 
V Multifactorial PH • Blood, metabolic and systemic 
disorders  
• Chronic renal failure 
Table 1.1: PH classification (Simonneau et al., 2013) 
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 Over the last three decades, significant attention has been given to the 
investigation of  pulmonary arterial hypertension (PAH, Group 1), with significant strides 
made in understanding the development of, and potential treatment options in the disease 
(Hemnes & Humbert, 2017). PAH is recognized as a progressive disorder during which 
thrombosis, proliferation, inflammation and remodeling of the lung vasculature leads to a 
narrowing of pulmonary arteries and subsequent right ventricular overload, dilation, and 
ultimately myocardial failure (Galie, Palazzini, & Manes, 2010). Unfortunately, the 
symptoms of PAH are often subtle, non-specific and can easily be missed in a physical 
examination (Nauser & Stites, 2001), which may in part contribute to the ‘silence’ of the 
disease, and the poor prognosis once PAH has been diagnosed.  
 PAH is a relatively rare condition, with a prevalence of approximately 320 cases 
per 100,000 (Strange et al., 2012), and the current median survival for PAH patients is 
approximately 7 years from diagnosis (McGoon et al., 2013). This is an increase of close 
to 5 years over the last three decades, likely driven by an increase in available treatment 
options. The increasing mean age of patients at diagnosis, which has risen from 36  15 
years in the mid 1980’s to 50  14 and 65  15 years would suggest greater prevalence in 
those of advancing age. While this shift may also represent an increased awareness of the 
condition (Rosenkranz, 2015), no cure exists, and patients suffer from a significantly 
decreased quality of life. Symptoms of PAH include fatigue, dyspnea, shortness of breath 
and severe exercise limitation (Barnes, Brown, Burns, & Williams, 2019). Indeed, this 
reduction in functional capacity has been used specifically to describe PAH symptoms by 
the New York Heart Associations and World Health Organization. Here, poorer physical 
capacity is directly linked to disease progression, with Group I patients begin described 
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as asymptomatic with normal activity, to Group IV who present with symptoms even at 
rest (Rubin, 2004). 
 
Background to the Problem 
 The pathophysiology of PAH is complex, and as such, treatment is challenging 
(Bogaard, Abe, Vonk Noordegraaf, & Voelkel, 2009; Galie et al., 2014; Galie & Manes, 
2013), with clinical decisions based on severity of disease, etiology, and response to drug 
therapy (Steiropoulos, Trakada, & Bouros, 2008). In a recent review, the most common 
strategies in battling PAH were outlined, including pharmacological and behavioral 
approaches that have shown promise in human and animal studies (Provencher & 
Granton, 2015). Endothelin receptor antagonists (ERA’s) including Bosentan, 
Ambrisentan and Macicentan work by increasing vasodilation, and have shown promise 
in improving functional capacity, hemodynamics, and reduced morbidity and mortality 
when comparted to placebo. Additionally, the use of phosphodiesterase type 5 (PDE 5) 
inhibitors and guanylate cyclase stimulators that also increase vasodilation by targeting 
reduced nitric oxide bioavailability continue to show promising results. In this category, 
Sildenafil, Tadafil and Riociguat have been most extensively studied, with improved 
exercise tolerance, hemodynamics, and reduced clinical worsening all reported. Finally, 
the use of prostanoids and prostacyclin receptor agonists have been explored. Similar to 
PDE 5-based therapies, drugs such as Epoprostanol, Ilioprost and Selexipag are designed 
to manipulate the prostacyclin pathway and increase vasodilation. While this group of 
drugs has shown some promise, the challenge of delivery and inconsistency in efficacy 
warrants further research (Provencher & Granton, 2015).  
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 Importantly, even under optimal pharmacological treatment, PAH patients still 
suffer from reduced quality of life and significant exercise limitation (Pandey et al., 
2015). As a result, a growing body of work has considered the use of exercise 
interventions as an alternative therapeutic approach. Exercise is well known to improve 
outcomes in cardiopulmonary diseases such as left heart failure (Cattadori, Segurini, 
Picozzi, Padeletti, & Anza, 2018; Ding, 2017; Pearson, Mungovan, & Smart, 2017), 
Chronic Obstructive Pulmonary Disease (Blondeel, Demeyer, Janssens, & Troosters, 
2019; Mohammed, Derom, Van Oosterwijck, Da Silva, & Calders, 2018) and 
hypertension (Boutcher & Boutcher, 2017; Moraes-Silva, Mostarda, Silva-Filho, & 
Irigoyen, 2017), however, understanding on the effectiveness of exercise as a tool in 
managing PAH is still in its infancy.  
 Individuals with PAH have significant exercise intolerance (Babu, Arena, et al., 
2016; Neder et al., 2015). Patients consistently present with lower maximal aerobic 
capacity, reduced ventilatory threshold, lower muscle strength, as well as early-onset 
dyspnea and fatigue during exercise. This blunted exercise capacity, coupled with 
cardiopulmonary symptoms may be the main reason that exercise was initially 
contraindicated for PH patients (Desai & Channick, 2008). However, the increasing 
number of clinical trials demonstrating the benefits of exercise in PAH patients (Babu, 
Padmakumar, Maiya, Mohapatra, & Kamath, 2016; Buys, Avila, & Cornelissen, 2015; 
Pandey et al., 2015) has led to a push for its inclusion as a means of managing the 
disease. Additionally, there is a desire to more fully understand the pathophysiology of 
exercise intolerance, and how this might be overcome either through pharmacological 
and/or behavioral interventions.  
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 Undoubtedly, exercise limitation in PAH is related to ‘central’ dysfunction. The 
failing right ventricle (RV) is unable to meet the cardiac output demands of exercise 
(Sun, Hansen, Oudiz, & Wasserman, 2001). However, a growing body of evidence 
suggests that peripheral dysfunction, specifically related to skeletal muscle abnormalities, 
are key contributors to exercise intolerance. A reduction in strength and power, shift 
toward anaerobic metabolism, atrophy, and greater percentage of type II muscle fibers 
have all been demonstrated in PAH patients (Batt, Ahmed, Correa, Bain, & Granton, 
2014; de Man et al., 2011; Mainguy et al., 2010b; Malenfant, Potus, Mainguy, et al., 
2015; Manders et al., 2012; Manders, Rain, et al., 2015; Manders, Ruiter, et al., 2015). 
Mechanistically, mitochondrial enzymes governing metabolism are altered (M. B. Brown 
et al., 2015; Malenfant, Potus, Fournier, et al., 2015), muscle fiber cross sectional area is 
reduced, atrophic signaling is upregulated (de Man et al., 2011) and calcium handling in 
myocytes is dysfunctional (Batt et al., 2014). While central and peripheral maladaptations 
both contribute to exercise intolerance, one area that remains understudied is the effect of 
skeletal muscle blood flow during exercise in PAH. It is not known if reductions in 
cardiac output may have downstream effects of reduced muscle blood flow, particularly 
during exercise, and this idea requires a full exploration in PAH (Figure 1.1). As the vast 
majority of cardiac output is directed toward working muscles during exercise (Hearon & 
Dinenno, 2016), directly measuring skeletal muscle blood flow during exercise would 
provide crucial mechanistic insight into exercise intolerance, and potentially elucidate a 
novel target for therapeutic intervention.  
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Figure 1.1: Exercise intolerance in PAH, adapted from Vescovo et al. (1998) 
 
Significance 
 As mentioned, vascular dysfunction forms the basis of PAH development. As 
such, pharmacological treatments have centered on improving vasoreactivity by inducing 
vasodilation. Three main pathways are targeted as a means to combat vascular 
dysfunction (Figure 1.2).  One such pathway is the nitric oxide (NO) pathway, which is 
made bioavailable via a group of enzymes known as nitric oxide synthases (NOS) acting 
on the substrate L-arginine, inducing vasodilation via the second messenger cyclic 
guanosine monophosphate (cGMP). It has been long established that NO acts as a potent 
vasodilator and therefore blood-flow modulator (Ignarro, 1989), however, it also directly 
affects skeletal muscle function via altered glucose and calcium signaling, altered 
mitochondrial respiration and contractile function. (Stamler & Meissner, 2001).  
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Figure 1.2: Pharmacological treatment in PAH, adapted from Schulze-Neick and 
Beghetti (2010) 
 
 Manipulation of this pathway is crucial, as it has been shown to be downregulated 
in PAH patients (Cua et al., 2011; Giaid & Saleh, 1995; Pullamsetti et al., 2005) and 
animal models (Alef et al., 2011; Goret, Tanguy, Guiraud, Dauzat, & Obert, 2008). While 
work continues on pharmacological treatment via the classic NO pathway, a promising 
alternative method of upregulating NO has recently been identified.  
 Nitrate (NO3-) and nitrite (NO2-) anions, initially thought to be a byproduct of NO 
metabolism, are now known to be potential donors of NO when reduced, particularly in 
hypoxic tissue (Alef et al., 2011; Friis, Steenholt, Lokke, & Hansen, 2017). Enzymatic 
reduction of NO3-/NO2- is facilitated primarily by hemoglobin, myoglobin, and xanthine 
oxidoreductase (XOR), resulting in an increased bioavailability of NO outside the 
traditional L-arginine-NOS-NO pathway (Zuckerbraun et al., 2010). Importantly, a 
simple way of increasing circulating nitrate and nitrite is via the consumption of green 
8 
leafy, and root vegetables. Dietary nitrate is absorbed in the gastrointestinal tract, and 
converted to nitrite via facultative bacteria in the saliva (Gladwin et al., 2005; Lundberg 
et al., 2009). The subsequent circulating nitrite is then reduced to NO in an oxygen-
independent manner, particularly in tissues undergoing metabolic stress (Ataya, Tzeng, & 
Zuckerbraun, 2011). This evidence points to a promising, alternative method of 
increasing NO bioavailability that could be harnessed in PAH via the administration of 
dietary nitrate. Indeed, the metabolic perturbation brought about by exercise may mean 
this pathway is ideally suited as a target for improving skeletal muscle function and 
combating exercise limitation (Woessner, McIlvenna, Ortiz de Zevallos, Neil, & Allen, 
2018). 
 The majority of studies investigating the effectiveness of dietary nitrate as either a 
therapeutic option or as an ergogenic aid have involved the use of beetroot juice or 
associated beet-containing products. Beetroot contains high level of nitrates, and after 
administration has been shown to increase circulating levels of NO3- and NO2- (Mills, 
Khatri, Maskell, Odongerel, & Webb, 2017). A significant body of evidence has 
demonstrated that beet consumption can improve exercise performance in healthy and 
patient populations (A. M. Jones, 2014a). Interestingly, recent work has shown that 
beetroot juice (BRJ) may specifically increase exercise tolerance in individuals with 
cardiovascular disease (Coggan et al., 2018; Coggan, Leibowitz, Spearie, et al., 2015; 
Kenjale et al., 2011) , and in related animal models (Alef et al., 2011; Ataya et al., 2011; 
Ferguson et al., 2013; Ferguson et al., 2016; Zuckerbraun et al., 2010), with one trial 
specifically examining its effectiveness in PAH (Henrohn et al., 2018). While this work 
provides rationale for the investigation of dietary nitrate as an ergogenic aid in PAH, the 
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mechanisms related to its potentials effectiveness are somewhat speculative. Specifically, 
it is unknown whether BRJ could augment exercising blood flow in PAH, and 
subsequently improve exercise performance.   
 
Purpose 
 Characterizing skeletal muscle blood flow at rest and during exercise in PAH is 
critical in developing a fuller understanding of exercise limitations in the disease. 
Similarly, targeting the aforementioned alternative NO3- – NO2- – NO pathway via the 
supplementation of BRJ provides a novel approach to potentially improve exercise 
performance. This research directly measured, for the first time, exercising skeletal 
muscle blood flow in an animal model of PAH, providing insights as to how this 
maladaptation may contribute to exercise intolerance. Additionally, the use of a readily 
available, non-pharmaceutical supplement with the potential to augment blood flow and 
improve exercise performance was investigated, providing new details as to the potential 
use of dietary nitrate as an ergogenic aid and therapeutic option in PAH. Results of the 
research will underscore the importance of reduced blood flow and skeletal muscle 
dysfunction in what has traditionally been considered a ‘cardiopulmonary disease’, while 
providing new mechanistic insight in to the nature of tissue adaptations beyond the heart 
and lungs. Finally, this work will add to the growing body of knowledge on the 
effectiveness of dietary nitrate as a strategy to improve exercise performance in disease 
states, while exploring the handling of dietary nitrate in multiple tissues, adding the 
mechanistic insight in this area (Figure 1.3). 
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Figure 1.3: Hypothesis outline 
  
1. Specific Aim 1: In a rat model of PAH, skeletal muscle blood flow will be 
characterized at rest and during moderate intensity exercise. 
Hypothesis 1.1 – Skeletal muscle blood flow will be significantly reduced at rest and 
during exercise in a PAH rat model, when compared to healthy controls.  
2. Specific Aim 2: To determine if an acute dose of dietary nitrate via beetroot juice 
(BRJ) supplementation improves exercising skeletal muscle blood flow and energetics in 
a rat model of PAH. 
Hypothesis 2.1 – Animals supplemented with BRJ will demonstrate increased blood flow 
in comparison to those supplemented with placebo.  
Hypothesis 2.2 - Animals supplemented with BRJ will demonstrate reduced reliance on 
anaerobic metabolism via lower blood lactate accumulation at rest and during exercise. 
3. Specific Aim 3 – To determine if an acute dose of dietary nitrate will improve function 
by measuring the impact of BRJ on: 
a. volitional running as assessed with 24-hour wheel monitoring in repeated trials  
b. Maximal aerobic capacity (VO2max) as assessed by maximal treadmill running test in 
repeated trials 
c. Whole body muscle strength using a rat grip-strength test in repeated trials  
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Hypothesis 3.1 – BRJ supplementation will result in a significant increase  in exercise 
function through improved VO2max, strength and increased volitional running distance in 
both PAH and control rats, compared to those supplemented with placebo.  
 
Methodology 
 The purpose of this investigation was to characterize skeletal muscle blood flow 
in a monocrotaline (MCT) model of PAH (Gomez-Arroyo et al., 2012), and subsequently 
employ a dietary supplement that may increase blood flow and improve exercise 
performance. A prospective, randomized, counterbalanced, placebo-controlled trial was 
used to examined the aforementioned aims across four groups; PAH rats supplemented 
with BRJ (MCT BRJ); PAH rats supplemented with placebo (MCT PL); healthy control 
rats supplemented with BRJ (CON BRJ); healthy control rats supplemented with placebo 
(CON PL). Counterbalanced functional exercise tests were carried out pre and post 
disease induction, with a final, terminal experiment examining blood flow during 
exercise under either BRJ or PL conditions. The independent variables in the study 
include health/disease status (MCT vs. CON) and dietary supplement administered (BRJ 
vs. PL). Dependent variables include direct and indirect measures of disease severity, 
skeletal muscle blood flow and capillarization, whole blood lactate, plasma and skeletal 
muscle NO2-/NO3- post supplementation, and functional exercise performance in 
maximal aerobic testing, voluntary running distance, and grip strength. Quantitative 
analysis was used to determine the effect of disease status and supplementation on the 
dependent variables.  
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Outline of Dissertation 
 The dissertation consists of five chapters. Chapter one outlines the problem and 
provides rationale for the investigation, as well as listing specific aims/hypothesis and 
briefly outlining the methodology. Chapter two contains a review of the relevant 
literature, including a description and pathophysiology of PAH, treatment options, 
benefits of exercise, importance of blood flow during exercise, and findings on the use of 
dietary nitrate as an intervention in health and disease. Chapter three describes the 
research design and methodological approach. Results are presented in chapter four. 
Implications of the results, potential future research questions and limitations are outlined 
in chapter five.  
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Chapter Two: Literature Review 
Introduction 
 PAH is a rare disease with a varied and complex pathophysiology. Significant 
research in patients and animal models has provided new insights into the mechanisms of 
disease onset and progression, however, a cure remains elusive. Treatment options are 
expanding, yet as this stage pharmacological interventions have largely been limited to 
addressing symptom management. Interest in exercise as a means of limiting disease 
progression and improving quality of life is growing, and a convincing body of evidence 
points to the benefits of exercise in PAH. While patients display significant exercise 
intolerance, there is limited understanding into the mechanisms behind this problem. 
Specifically, the consequence of skeletal muscle dysfunction as it relates to exercise 
performance requires further work. Earlier studies have shown that metabolic and 
morphological changes play a role in limiting exercise capacity, however it is not known 
to what extent blood flow to exercising muscle is limited in the disease. The use of a 
well-established animal model of PAH will allow for a direct mechanistic investigation of 
muscle blood flow at rest and during exercise, and potentially elucidate a therapeutic 
target to improve exercise tolerance, and ultimately, quality of life for PAH patients. 
Finally, the evidence pertaining to the use of dietary nitrate as an ergogenic aid in health 
and disease will be considered, with specific reference to its potential benefits in 
modulating muscle blood flow and exercise tolerance in PAH. 
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PAH Pathophysiology 
 In the late 1950’s, after the advent of cardiac catheterization, PAH (also referred 
to as primary or idiopathic pulmonary hypertension) was recognized as a unique 
condition in which elevated pulmonary artery pressures were measured without the 
presence of coexisting cardiopulmonary diseases such as stenosis, septal defect, 
emphysema and pulmonary embolism. This early recognition was useful from a 
classification stand-point, however, it was still difficult to diagnose PAH as symptoms 
were often non-specific and common to other known cardiovascular diseases (Whitaker 
& Heath, 1959).  
 While the exact pathogenesis of PAH is still largely unknown, it is now widely 
accepted that endothelial dysfunction initiates the disease process (Toshner, Tajsic, & 
Morrell, 2010). Pulmonary arteries undergo remodeling via the proliferation of 
endothelial and smooth muscle cells (Humbert, 2010), leading to intimal and medial 
thickening and the development of plexiform lesions (Sutendra & Michelakis, 2014). 
These plexiform lesions have been described as a hallmark of PAH progression, (Abe et 
al., 2010) as they have been implicated in the vascular dysfunction described. Several 
pathways have been associated with the remodeling process. Matrix metalloproteinases 
(MMPs), which are linked to endothelial and smooth muscle cell proliferation and 
migration, have been shown to be upregulated in PAH patients (Lepetit et al., 2005). 
Additionally, elevated levels of endothelin-1 (ET-1) in the vascular endothelium and 
plasma have been recognized (Rosenblum, 2010). ET-1 has been shown to induce cell 
growth and downregulate apoptosis, and can be as much as 20-fold higher in patients 
compared to healthy controls (Stewart, Levy, Cernacek, & Langleben, 1991). 
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Prostacyclin, a mediator of endothelial cell function, is downregulated in PAH. This can 
lead to smooth muscle cell proliferation, platelet aggregation and vasoconstriction in 
small, medium and large pulmonary arteries (Tuder et al., 1999). Additionally, potassium 
channel dysfunction and/or downregulation may play a role in the vasoconstrictive nature 
of disease pathology (Newman et al., 2004). A further area that has been widely 
considered is endothelial dysfunction via altered growth factor signaling, primarily 
through the TGF- superfamily. Patients with idiopathic and familial PAH have been 
shown to harbor a mutation in the gene that encodes bone morphogenetic protein receptor 
type II (BMPR-2) (Humbert, 2010). While the penetrance of this mutation is rather low 
(10-20%), patients without the mutation also demonstrate a reduced expression of 
BMPR-2 (Atkinson et al., 2002). This is important, as alterations in BMPR-2 signaling 
have been shown to increase cell proliferation and decrease apoptosis in vascular cells 
(Hemnes & Humbert, 2017). While altered BMPR-2 signaling seems to represent the 
most promising genetic basis for PAH pathogenesis, further studies are attempting to 
more fully understand the genetic mutations that may predispose one to the disease (de 
Jesus Perez, 2016). 
 
 Right Ventricular Dysfunction  
 While pulmonary vascular remodeling is a central component of PAH, the 
subsequent increased pulmonary vascular resistance and increased strain on the RV is the 
hallmark of disease diagnosis (Bogaard, Abe, et al., 2009). Patient survival has been 
linked to RV function (Sandoval et al., 1994), and as such, there has been interest in 
understanding the mechanisms of right ventricular maladaptation. The RV is crescent 
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shaped, with a thinner wall and lower surface area in comparison to the left ventricle 
(LV). While this increases compliance, the RV is subject to dilation with increased 
pressure (Chin, Kim, & Rubin, 2005). Subsequent wall stress leads to increased oxygen 
demand, and the RV adapts by increasing muscle mass. This hypertrophy, thought to be 
driven by structural, neurohormonal and inflammatory alterations initially ensures the RV 
meets cardiac output demands (Bogaard, Abe, et al., 2009), however, sustained pressure 
increases can lead to RV failure (Archer, Fang, Ryan, & Piao, 2013). This ‘transition’ 
from compensatory to decompensatory hypertrophy is a critical component of PAH, 
particularly because RV function is the best predictor of clinical worsening in the disease 
(van de Veerdonk et al., 2011). In conjunction with the morphological and functional 
changes outlined, there is evidence of metabolic changes in the adapting RV. Initially a 
metabolic switch occurs, driven in part by an upregulation of pyruvate dehydrogenase 
kinase (PDK), leading to an increased reliance on glucose metabolism. While this shift 
decreases ATP production, it has been shown in experimental PAH models that it may 
also impair myocyte electrical contractile function (Piao, Fang, et al., 2010; Piao, 
Marsboom, & Archer, 2010). Interestingly, more recent work has demonstrated this 
metabolic shift may not continue through decompensation and RV failure. Instead, a 
downregulation of PDK and angiogenic factors via inhibition of hypoxia inducible factor-
1 (HIF1) signaling leads to myocardial ischemia, and ultimately deterioration of the RV 
(Sutendra et al., 2013).  In addition to the metabolic perturbation outlined, it has been 
demonstrated in patients and animal models that right heart failure may also be a 
consequence of myocardial fibrosis and reduced capillarity (Bogaard, Natarajan, et al., 
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2009; Philip et al., 2019), adding to the complexity in describing the precise mechanisms 
by which RV function declines.   
Muscle Dysfunction  
 Muscle dysfunction is being increasingly recognized as an important component 
of cardiopulmonary disease phenotype, including in left heart failure and COPD (Maltais 
et al., 2014; Pina et al., 2003), and this phenomenon has been receiving greater attention 
in PAH. In early work, Vescovo et al. (1998) demonstrated skeletal muscle dysfunction 
in a heart failure (HF) rat model. Specifically, it was noted that myosin heavy chain 
expression shifted toward faster isoforms, at the expense of slower-fiber phenotypes. 
Additionally, resting blood flow was statistically reduced in the soleus of the HF rats, but 
not in the extensor digitorum longus (EDL) muscle. Later work on animal models of 
PAH have led to a greater understanding of skeletal muscle abnormalities, as well as the 
identification of pathways central to these changes. In a severe PAH animal model, de 
Man et al. (2011) demonstrated a reduction in diaphragm muscle fiber cross sectional 
area when compared to controls. Interestingly, this difference was not seen in the EDL, 
leading the authors to propose a ‘diaphragm-specific’ atrophic phenotype. While this 
finding is important, it could be argued that only analyzing the EDL as a surrogate for 
skeletal muscle fiber loss may result in missed maladaptations elsewhere. Nevertheless, 
increased expression of the E3-ligases MAFbx and MuRF-1 were identified in PAH rat 
diaphragms, indicating that atrophy may be driven by muscle proteolytic activity. From a 
functional perspective, the same study noted a significantly reduced force production in 
skinned diaphragm fibers, which again was not seen in the EDL. The greatest strength of 
this work was to connect the animal model findings to that of PAH patients. 
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Maladaptations in the rat model were reflected in the diaphragm of patients, indicating a 
respiratory-muscle specific atrophy and reduction in force generating capacity. This work 
was later complimented by Ahn, Empinado, Al-Rajhi, Judge, and Ferreira (2013), who 
investigated diaphragm contractile function in a PAH mouse model. Here, PAH induction 
resulted a 25% decrease in cross sectional area (CSA) of diaphragm fibers, with a similar 
reduction in maximal and submaximal tetanic force production. Of greatest significance 
may the finding that shortening velocity and peak power of fibers were reduced by 40% 
and 63% respectively in the PAH model, variables that translate more closely to 
diaphragm action in vivo (Ahn et al., 2013). Interestingly, no differences in myosin heavy 
chain expression were noted, and it was speculated that in this case, reduction in muscle 
function may be due to either an upregulation of inflammatory cytokines, which has been 
previously demonstrated in PAH (Price et al., 2012), or via post-translational changes 
affecting myofibrillar function. The aforementioned findings on the diaphragm were 
further complimented by mechanistic work focusing on sarcomere action in a PAH rat 
model (Manders et al., 2012). Again, force-generating capacity was reduced when 
compared to controls, specifically in fast twitch fibers. In an attempt to understand this 
phenomenon, single muscle fibers were exposed to increasing calcium concentrations. It 
was noted that at submaximal activation levels, calcium sensitivity was reduced in PAH 
rats, leading to the idea that sarcomeric dysfunction plays a role in reduced force 
generating capacity. Finally, it has been shown that PAH patients have lower inspiratory 
and expiratory pressures when compared to healthy control subjects (Kabitz et al., 2008; 
Meyer et al., 2005), lending weight to the idea that respiratory muscle dysfunction 
translates directly into reduced ventilatory capacity.  
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 While there is clear evidence supporting the idea of muscle dysfunction in the 
diaphragm of PAH patients and animal models, recent work has identified abnormalities 
in other muscle groups. It has been shown that forearm muscle strength is reduced in 
PAH patients, and that this reduction is closely linked to disease severity (Bauer et al., 
2007). Similarly, fast twitch fibers in the vastus lateralis of PAH patients have lower 
contractile function when compared to controls, potentially due to a reduction of cross-
bridges secondary to myosin protein loss (Manders, Ruiter, et al., 2015). This atrophic 
phenomenon was explored in greater detail in a wide-ranging mechanistic analysis of 
PAH patients quadriceps muscle dysfunction (Batt et al., 2014). Patients demonstrated a 
lower percentage of Type I fibers after biopsy, with a concurrent reduction in Type I 
cross sectional area. Phosphorylated-AKT and -p70S6 kinase signaling pathways, both 
recognized as important for muscle hypertrophy, were downregulated in PAH muscle. 
Additionally, mRNA associated with ubiquitin ligase pathways related to proteolysis of 
muscle, including muscle ring finger protein 1 (MuRF 1) and antrogin-1 were increased 
compared to controls, suggesting that both reduced hypertrophy and increased proteolysis 
may play a role in muscle CSA reduction.  
 Metabolic abnormalities, similar to those outlined in the RV, have been identified 
in skeletal muscle. Proteins involved in mitochondrial oxidative metabolism, including 
NADH, complex III cytochromes and complex V ATP synthase are decreased in the 
vastus lateralis of PAH patients.  Conversely, proteins involved in pyruvate (non-
oxidative) metabolism (lactoylglutathione lyase) and gluconeogenesis (fructose-1,6-
biphosphatase) have been shown to be increased (Malenfant, Potus, Fournier, et al., 
2015), adding weight to the idea of a ‘metabolic shift’ in the disease. These findings 
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supported earlier work showing an increased phosphofructokinase/3- hydroxyacyl-CoA-
dehydrogenase (PFK/HADH) ratio in the quadriceps of PAH patients, again suggesting a 
greater reliance on energy metabolism via anaerobic means.  
 Finally, morphological changes, in addition to atrophy, have been noted in PAH. 
Specifically, it has been shown that microcirculation loss is present in the disease. CD31+ 
staining of the quadriceps muscle confirmed capillary rarefaction, driven in part by a 
reduction in miR-126 expression, as well as decreased activation of RAF and ERK 
pathways, both effectors of VEGF/MAP-dependent angiogenesis (Potus et al., 2014).  
 Figure 2.1 outlines the intrinsic and systemic factors that have been postulated as 
playing a role in skeletal muscle abnormalities outlined. While it is clear a myopathy 
exists in PAH patients, more work is required to fully understand the impact of muscle 
dysfunction in terms of disease development, quality of life, and importantly, if 
alternatives therapies may be directed in this area. Additionally, as muscle function is 
directly connected to exercise performance, further work must address the mechanistic 
basis of muscle function during whole-body exercise. This critical missing piece may 
help elucidate the importance of peripheral factors in exercise limitation, particularly due 
to the growing notion that exercise is a critical component in improving quality of life for 
PAH patients. 
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Figure 2.1: Extrinsic and intrinsic factors that contribute to muscle dysfunction in PAH. 
Adapted from Manders, Rain, et al. (2015) 
 
Pathophysiology of Exercise Intolerance in PAH 
 The central (heart/lung) and peripheral (muscle) abnormalities described both 
play an important role in the significant decline in exercise capacity (Sun et al., 2001). 
Understanding this phenomenon is crucial, as it has been shown that exercise intolerance 
is one of the primary factors limiting quality of life, as well as being closely related to 
clinical worsening in PAH (Tran, Lau, Celermajer, Davis, & Cordina, 2018). The 
increased use of exercise testing and rehabilitation programs has shed light on the 
mechanisms behind exercise intolerance, with a greater focus being placed on exercise as 
a therapeutic intervention. Connecting the dots between central and peripheral 
abnormalities in response to exercise is vital as it may provide further data on novel 
targeted therapies, and/or lead to a standardization of exercise interventions in the 
disease, which currently do not exist.  
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Cardiac Dysfunction and Exercise Intolerance 
 As noted previously, maladaptive remodeling in the RV is characterized by initial 
hypertrophy as a consequence of increased afterload, progressing toward chamber 
dilation and eventually systolic dysfunction with reduced cardiac output. Additionally, it 
has been shown that myocyte orientation may limit the RV’s ability to maintain stroke 
volume, in comparison to a more efficient contractile function in the LV. Several studies 
have questioned how the adapting RV may impact exercise performance. Using MRI and 
right heart catheterization to measure cardiac function and pulmonary pressures, 
Holverda et al. (2006) determined that PAH patients were unable to significantly increase 
stroke volume (SV) with the onset of exercise, in contrast to healthy control subjects. 
Additionally, right ventricular end diastolic volume increased in PAH, but crucially, left 
ventricular end diastolic volume decreased during exercise. This can be explained by a 
reduction in myocardial contractility, and the anatomical connection between the RV and 
LV. As RV diastolic filling increases in PAH, LV diastolic filling decreases. This again is 
critical, as a central factor in maintaining exercise tolerance is the ability to increase 
cardiac output to meet the increased metabolic demands of exercising muscle. These 
findings were mirrored by Sun et al. (2001), who retrospectively analyzed cardiac 
function data from cardiopulmonary exercise tests (CPET) in 53 PAH patients. While 
peak oxygen consumption and peak work rate were significantly lower in PAH patients, 
it was noted that maximal heart rate was also reduced, despite each test resulting in 
workloads above the ventilatory threshold. This is further supported the work of 
Provencher et al. (2006) who also described chronotropic incompetence in PAH patients. 
Interestingly, both reduced stroke volume and heart rate responses to exercise were 
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independently related to 6-minute walking distance, indicating that a heart rate increase 
likely cannot overcome the reduced stroke volume of PAH patients. Mechanistically, it 
has been proposed that a downregulation of myocardial -adrenergic activity can in part 
explain the observed reduced maximal heart rate (Manders, Rain, et al., 2015; Provencher 
et al., 2006). RV hypertrophy, as a consequence of PAH, can lead to dyssynchrony and 
atrioventricular uncoupling (Badagliacca et al., 2017; Hill et al., 2012; Marcus et al., 
2008; Spruijt et al., 2015). During exercise, it has been demonstrated that impaired 
contractility in the face of increased afterload can disrupt normal RV-arterial coupling, 
and this may be because contractility is already at maximal levels at rest. Specifically, 
PAH patients are unable to match contractility to afterload with the onset of exercise 
(Spruijt et al., 2015). Additionally, RV dyssynchrony (or uncoordinated contraction) 
(Tran et al., 2018) has been demonstrated in PAH, and it has recently been shown to be a 
predictor of reduced exercise capacity in the disease (Badagliacca et al., 2017).  
 In addition to mechanical abnormalities, previously described metabolic 
adaptations in the RV may also play a role in reduced exercise capacity. It stands to 
reason that with reduced capillarity (Bogaard, Abe, et al., 2009), and reduction in 
oxidative enzymes regulating energy metabolism (Piao, Marsboom, et al., 2010), the 
ability of the RV to adapt to the increased energy demands of exercise will be blunted. As 
the myocardium predominantly uses aerobic means to generate ATP, sufficient blood 
flow is necessary to ensure adequate energy supply. Reduced capillarization, in addition 
to the lower coronary flow present in PAH (van Wolferen et al., 2008) results in 
myocardial ischemia that may be exacerbated during exercise (Tran et al., 2018). It has 
been shown that RV adaptations may be more evident during exercise in PAH (Nootens, 
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Wolfkiel, Chomka, & Rich, 1995), and the outlined RV dysfunction undoubtedly plays a 
role in exercise intolerance. Indeed, a recent review determined that RV function and 
exercise capacity were strong predictors of survival in PAH (Humbert et al., 2010). 
Limiting exercise impairment to central deficiencies and the maladapted RV would miss 
the systemic nature of exercise responses, with pulmonary and skeletal muscle function 
also crucial in determining exercise capacity in PAH.  
 
 Pulmonary Dysfunction and Exercise Intolerance 
 Pulmonary vascular remodeling as a result of endothelial dysfunction is a central 
component of PAH pathogenesis (Galie et al., 2010). In order to maintain the relative 
low-pressure system in the pulmonary circulation, the ability of pulmonary vessels to 
distend with the increased blood flow demands of exercise is crucial, particularly as this 
will in turn reduce RV wall stress. The maladapted pulmonary arteries, characterized by 
endothelial proliferation and vascular stiffness, are compromised in their ability to 
vasodilate to increase lung blood flow as needed with the onset of exercise. As such, an 
increase in pulmonary vascular resistance (PVR) is seen, leading to ventilation-perfusion 
mismatching. Underscoring the interconnectedness of exercise responses, this continued 
increased PVR reduces RV output, feeding forward to a lower LV preload, stoke volume 
and cardiac output (Waxman, 2012). Furthermore, early hyperventilation (increased rate 
of breathing) and dyspnea (shortness of breath) are common signs of reduced exercise 
capacity in PAH (Sun et al., 2001). In early work it was demonstrated that minute 
ventilation (VE) at any given level of carbon dioxide production (VCO2) is higher for 
PAH patients, and the increase with progressive exercise is more profound in the disease. 
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This would indicate ventilatory inefficiency, more so than ventilation limitation, as 
patients are able to achieve maximal ventilation levels similar to healthy control subjects 
(D'Alonzo et al., 1987). Indeed, two further mechanisms that may result in 
hyperventilation/dyspnea with exercise in PAH have been proposed. The lower cardiac 
output and reduced capacity for oxidative metabolism leads to a systemic reduction in 
pH, driven by increased lactate and hydrogen ion (H+) accumulation (Sun et al., 2001). 
Additionally, the increased PVR during exercise increases right atrial pressures to the 
extent to which they may exceed those in the left atrium. As a result, venous blood may 
be shunted to the left atrium via a patent foramen ovale, and ultimately into the systemic 
circulation. This deoxygenated, acidic blood can subsequently lead to an increase in 
ventilation, driven primarily by systemic chemosensitivity (Sun, Hansen, Oudiz, & 
Wasserman, 2002). Interestingly, the incidence of left to right shunting may be high in 
PAH, with the aforementioned abnormalities being seen is as many as 45% of patients 
tested (Sun et al., 2002).  
  
 Muscle Dysfunction and Exercise Intolerance 
 As outlined previously, there are multiple structural, mechanical and metabolic 
abnormalities identified in muscles of PAH animal models and patients. It has been 
demonstrated that exercise intolerance in PAH is only partially associated with altered 
central hemodynamics (i.e. reduced cardiac output), suggesting that peripheral 
mechanisms may also play a role. The onset of exercise and subsequent increased 
ventilation directs blood flow to diaphragm, which in trained individuals has been shown 
to increase by as much as 16% at high intensity workloads (Harms et al., 1998). This may 
26 
be particularly problematic in PAH as hyperventilation may lead to increased work of 
breathing, concomitant with a decreased overall cardiac output as previously described. 
While there are clearly diaphragmatic abnormalities in PAH, connecting respiratory 
muscle dysfunction specifically to exercise intolerance is challenging, due to the highly 
integrated response of the cardiovascular and muscular system to exercise stress. Breda et 
al. (2014) addressed this question by analyzing exercise capacity, hemodynamics and 
muscle function during a 6-minute walking and incremental exercise test in 16 PAH 
patients. As expected, patients had altered muscle fiber type, reduced force generating 
capacity and significantly lower maximal oxygen consumption (VO2max). Importantly, 
maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) were 
lower in the patient cohort, indicating compromised respiratory capacity during exercise. 
It was shown that MIP was negatively correlated with VO2max, indicting for the first time 
that respiratory function can be directly connected to exercise intolerance in PAH. 
Crucially, this connection held true even when correcting for changes in cardiac output. 
These findings were complimented by a second study that demonstrated MIP/MEP were 
related to 6-minute walk distance, number of steps and physical activity scores in 33 
PAH and chronic thromboembolic pulmonary hypertensive (CTEPH) patients (Aslan, 
Akinci, Yeldan, & Okumus, 2018). Finally, Saglam et al. (2015) analyzed physical 
activity history and 6-minute walking capacity of 31 PAH patients and connected 
exercise capacity to respiratory muscle function. It was determined that respiratory 
muscle function was lower in patients than controls, however, a novel finding was that 
this deficit can be used to delineate functional classes of PAH patients, as described in 
Chapter One.  
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 Peripheral skeletal muscle abnormalities have also been shown to limit exercise 
performance. Bauer et al. (2007) demonstrated that forearm muscle strength, measured 
via handgrip dynamometry, was reduced in PAH patients, and that a significant 
correlation existed between grip strength and disease severity as measured by the 6-
minute walk test. Similarly, it has been shown that quadriceps strength is positively 
correlated with VO2max in PAH patients (Mainguy et al., 2010b). In this study, not only 
was a connection made between muscle strength and exercise capacity, but an important 
metabolic link was observed. The oxidative capacity of muscle, as measured by levels of 
citrate synthase and 3-hydroxyacyl-CoA-dehydrogenase were reduced in PAH, and 
correlated with oxygen uptake (VO2) at the onset of heavy exercise. Furthermore, the 
importance of altered muscle morphology was highlighted, with VO2 also related to the 
number of capillaries per type I muscle fiber. This phenomenon has also been replicated 
in animal models of PAH. M. B. Brown et al. (2015) demonstrated a significant VO2max 
reduction in a rat model of PAH, and subsequent tissue analysis indicated greater reliance 
in non-oxidative metabolism via increase levels of glucose transporter 1 (GLUT-1) in 
both cardiac and skeletal muscle.  
 Several investigators have questioned how the interrelated concepts of oxygen 
delivery and metabolism may contribute to exercise intolerance in PAH. Potus et al. 
(2014) demonstrated that reduced muscle capillarity, measured via expression of CD31+ 
cells, was strongly correlated to VO2max in PAH patients, and went on to suggest 
microcirculation loss is likely related to exercise intolerance in the disease. These 
findings compliment the earlier work of Tolle, Waxman, and Systrom (2008), who 
determined that in mild PAH, systemic oxygen uptake/use abnormalities, potentially due 
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to capillary and/or mitochondrial dysfunction contribute to reduced exercise capacity. A 
further study by Malenfant, Potus, Mainguy, et al. (2015) more directly connected 
skeletal muscle microcirculation to a reduction in exercise performance. Quadriceps 
oxygenation was measured using near infrared spectroscopy (NIRS) during submaximal 
exercise both with and without supplemental oxygen. Interestingly, despite normal 
cardiac output responses to exercise PAH patients had lower skeletal muscle oxygenation 
that was not recovered with the addition of supplemental oxygen. While muscle blood 
flow as not directly measured, reduced capillarity was closely linked to diminished tissue 
oxygenation and exercise performance. PAH patients in this study had relatively high 
levels of functional capacity and it remains to be seen if exercise responses in a more 
severely afflicted cohort would be observed (Malenfant, Potus, Mainguy, et al., 2015).  
 It is clear that multiple factors play a role in limiting exercise in PAH (Figure 2.2 
Adapted from (Tran et al., 2018). A fundamental understanding of disease 
pathophysiology would indicate a strong association between central limitation and 
exercise performance. However, a growing body of work is recognizing that PAH is a 
systemic disorder, and the hallmark exercise intolerance patients experience is clearly 
also due to muscle dysfunction. Further work is required to fully understand the 
mechanisms behind this association. Oxygen uptake, metabolic disturbances and 
contractility decrements have all been characterized, however, a missing piece of the 
puzzle is a direct measurement of muscle blood flow at rest and during exercise in PAH. 
Adequate muscle blood flow is an essential factor in maintaining exercise, hence it 
should be measured directly in the disease. As patients present with lower maximal 
oxygen consumption and anaerobic thresholds, combined with a reduced oxidative 
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metabolic machinery, it stands to reason that reduced blood flow and subsequent early 
onset of anaerobic metabolism may help elucidate an important limiting factor in exercise 
intolerance. It is well known that exercise training and/or ergogenic aids can improve 
muscle performance, providing rationale for their use in PAH management.  
 
 
Figure 2.2: Central and peripheral determinants of exercise intolerance in PAH, adapted 
from Tran et al. (2018) 
 
 
Exercise as Therapy in PAH 
 PAH management is a complex process that involves continual clinical 
observation, assessment of risk and response to drug therapy, and the exploration of 
novel strategies that may lead to improved quality of life (Galie et al., 2014; Madonna & 
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Cocco, 2015; Provencher & Granton, 2015; Rosenkranz, 2015). While it is outside the 
scope of the current project to review current pharmacologic approaches to PAH 
management, detailed algorithms for treating the disease have been published (Hemnes, 
2014; Klinger et al., 2019; Provencher & Granton, 2015). Briefly, after referral to a 
specialized facility, vasoreactive testing is carried out, usually via the administration of 
inhaled NO. In vasoreactive patients, calcium-channel blockers are generally 
recommended, alongside close follow-up. In those patients that do not display acute 
vasoreactivity, PAH specific therapies as outlined in Chapter One are employed. In the 
most severe cases, intravenous epoprostinol is administered. Positive response to these 
drug interventions will mean continued therapy, however if they prove to be ineffective, 
lung transplantation is recommended (Provencher & Granton, 2015). While 
improvements in care have coincided with greater drug variety and availability, prognosis 
remains poor (McLaughlin, 2013). As such, the search for adjunctive therapies, including 
the use of exercise, has become a central theme in PAH management (Babu, 
Padmakumar, et al., 2016). As exercise intolerance is a common feature of disease 
progression (Babu, Arena, et al., 2016), there is rationale behind considering exercise 
training as a useful therapeutic tool. Due to the outlined pathophysiology and the 
inevitable exacerbation of cardiovascular stress brought about by exercise, it was initially 
contraindicated in this population (Desai & Channick, 2008). However, a strong body of 
evidence, including results from randomized clinical trials, now points to favorable 
outcomes for patients. Table 2.1 outlines the findings of exercise training interventions in 
PAH patients. 
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Author/ 
Year 
Participants Functional 
Class 
Intervention  
Description 
Results 
Saglam et 
al. (2015) 
n=29, male 
and female 
II and III 6 weeks inspiratory 
muscle training, 30 mins 
per day 
MIP/MEP  
expiratory 
volume 
 6-minute 
walk distance 
Kabitz et 
al. (2013) 
n=7, male 
and female 
III and IV 3 weeks in hospital, 12 
weeks home-based. 
Cardiovascular, gait and 
respiratory training 
 6-minute 
walk distance 
 peak 
inspiratory and 
expiratory 
pressure 
Weinstein 
et al. 
(2013) 
n=24, female I-IV 10 weeks cardiovascular 
training, 3 x per week 
 6-minute 
walk distance,  
 physical 
activity 
 fatigue 
Ley et al. 
(2013) 
n=20, male 
and female 
II and III In hospital 3 weeks 
cardiovascular/respiratory 
training 
 6-minute 
walk distance 
 pulmonary 
blood flow 
Becker-
Grunig et 
al. (2013) 
n=20, male 
and female 
II-IV 3 weeks in hospital, 12 
weeks home-based. 
Cardiovascular, gait, 
muscle and respiratory 
training 
 VO2max,  
 6-minute 
walk distance 
 pain 
 survival 
Chan et al. 
(2013) 
n=23, male 
and female 
I-IV 10 weeks cardiovascular 
training, 3 x per week 
 6-minute 
walk distance 
 quality of life 
 
Nagel et 
al. (2012) 
n=35, male 
and female 
II-IV 3 weeks in hospital, 12 
weeks home-based. 
Cardiovascular, gait, 
muscle and respiratory 
training 
 VO2max,  
 6-minute 
walk distance 
 quality of life 
 survival 
Grunig et 
al. (2012) 
n=21, male 
and female 
II-IV 3 weeks in hospital, 12 
weeks home-based. 
Cardiovascular, gait, 
muscle and respiratory 
training 
 6-minute 
walk distance 
 quality of life 
Grunig et 
al. (2012) 
n=183, male 
and female 
II-IV 3 weeks in hospital, 12 
weeks home-based. 
Cardiovascular, gait, 
 6-minute 
walk distance 
 quality of life 
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muscle and respiratory 
training 
Grunig et 
al. (2011) 
n=58, male 
and female  
II-IV 3 weeks in hospital, 12 
weeks home-based. 
Cardiovascular, gait, 
muscle and respiratory 
training 
 VO2max,  
 6-minute 
walk distance 
 quality of life 
Fox et al. 
(2011) 
n=22, male 
and female 
II and III 12 weeks in hospital and 
home-based. 
Cardiovascular and 
muscle training 
 VO2max,  
 6-minute 
walk distance 
 
Mainguy 
et al. 
(2010) 
n=5 II and III 12 weeks hospital based, 
cardiovascular and muscle 
training 
 6-minute 
walk distance 
 minute 
ventilation 
 
de Man et 
al. (2009)  
n=19, male 
and female 
II and III 12 weeks hospital based 
cardiovascular and 
quadriceps training 
 6-minute 
walk distance 
 quadriceps 
strength and 
endurance 
 workload at 
anaerobic 
threshold 
Shoemaker 
et al. 
(2009)  
n=2  6 weeks, 3 x per week 
cardiovascular 
 VO2max 
 quality of life 
Mereles et 
al. (2006) 
n=30, male 
and female  
II-IV 3 weeks in hospital, 12 
weeks home-based. 
Cardiovascular, gait, 
muscle and respiratory 
training 
 6-minute 
walk distance 
 quality of life 
Uchi et al. 
(2005) 
n=24, male 
and female 
III and IV 6 weeks, cardiovascular, 
gait, muscle and 
respiratory training 
 6-minute 
walk distance 
 resting heart 
rate 
 muscle 
strength 
Table 2.1: Exercise training in PAH, adapted from Zafrir (2013) and Babu, Padmakumar, 
et al. (2016) 
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The majority of exercise interventions include some cardiovascular training 
component (cycling, walking, treadmill), with several also including resistance (body 
weight, dumbbells) and respiratory training. Fortunately, trials have encompassed various 
functional classes, age ranges, and durations of intervention. Based on the data presented, 
it is clear that exercise is beneficial in improving functional capacity and quality of life in 
PAH patients, adding weight to the idea of increased physical activity as adjunctive 
therapy (Babu, Padmakumar, et al., 2016). While the majority of those studies were not 
‘mechanistic’ in design, studies using PAH animal models have shed greater light on the 
molecular changes brought about by exercise training (Nogueira-Ferreira et al., 2018).  
 M. B. Brown et al. (2017) determined that in a rat model of PAH induced via 
monocrotaline injection, 6 weeks of high intensity interval training (HIIT) reduced 
elevated pulmonary pressures, protected against RV hypertrophy, and improved cardiac 
function. At the skeletal muscle level, exercise trained rats had lower levels of GLUT-1, 
indicating a lower reliance on anaerobic metabolism and attenuation of the 
aforementioned glycolytic shift in the disease. Additionally, HIIT increased lung 
endothelial nitric oxide synthase (eNOS) expression. eNOS is recognized as a rate 
limiting enzyme in nitric oxide generation (Cocks et al., 2013), potentially increasing 
vasodilation in the lung, identified earlier as a barrier to exercise tolerance. Other animal 
studies have focused on the impact of exercise on the lung. Colombo et al. (2013) 
demonstrated that 3 weeks of treadmill running the same animal model increased lung 
hydrogen peroxide levels and vascular endothelial growth factor (VEGF), suggesting 
increased angiogenesis in response to training, concomitant with an improvement in RV 
function via echocardiography. Unsurprisingly, the majority of animal work has studied 
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the effects of exercise training on the RV. Treadmill running in PAH has been suggested 
to decrease RV hypertrophy via phosphorylation of glycogen synthase kinase (Colombo 
et al., 2013) and increase p-AKT protein expression, potentially upregulating anti-
apoptotic signaling (Colombo et al., 2015). In a novel experimental design, Moreira-
Goncalves et al. (2015) employed aerobic exercise either early or late in PAH induction. 
Both training groups improved cardiac function, explained in part by cardioprotective 
signaling via increased sarcoplasmic/endoplasmic reticulum calcium ATPase 2 
(SERCA2a) and decreased ET-1 mRNA. Additionally, early exercise intervention 
resulted in lower inflammatory markers and reduced fibrosis in the RV.  
 From both a mechanistic and functional perspective, there is sufficient evidence to 
suggest regular exercise may be beneficial in PAH. RV, lung and to a lesser extent, 
skeletal muscle molecular mechanisms of disease have been shown to be positively 
modulated by exercise training (Nogueira-Ferreira et al., 2018). While this alone would 
provide rationale for careful but purposeful integration of exercise as part of a PAH 
management plan, the severe exercise intolerance inherent in the disease may limit 
patient’s ability to reach a threshold of exercise needed to elicit the improvements 
necessary to improve quality of life (Manders, Rain, et al., 2015). With that said, novel 
strategies that might increase exercise tolerance in the short term may prove beneficial in 
bridging the gap to long term functional improvement.  
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Nitric Oxide and Dietary Nitrate in PAH 
 As outlined in Chapter One, the main therapeutic avenues in PAH target 
endothelial dysfunction, primarily by ameliorating vasoreacitve dysfunction in the 
disease. Extensive work has been carried out on drug therapies that modulate nitric oxide, 
endothelin-1, and prostacyclin pathways, all recognized as key to altering the disrupted 
vasodilation/vasoconstriction balance present in PAH (Abman, 2009; Antoniu, 2006; 
Asaki et al., 2015; Barnes et al., 2019; Beltran-Gamez, Sandoval-Zarate, & Pulido, 2015; 
Burger, D'Albini, Raspa, & Pruett, 2016; Chaumais et al., 2015; Klinger, 2011). Nitric 
oxide is a key regulator of endothelial function, having been recognized as important in 
modulating vasoreactivity, smooth muscle cell proliferation, platelet aggregation and 
endothelial cell apoptosis (Ahanchi, Tsihlis, & Kibbe, 2007; Ataya et al., 2011), and as 
such, investigation on how to manipulate NO in PAH has garnered great interest. NO is 
endogenously generated via the metabolism of L-arginine by a family of nitric oxide 
synthases known as endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS 
(iNOS) and ultimately induces vasodilation via the second messenger cGMP (Moncada 
& Higgs, 1993). Importantly, there is evidence to suggest this pathway is dysfunctional in 
PAH, potentially via increased levels of arginase, decreased NOS and/or eNOS 
uncoupling, in which superoxide ions are produced secondary to a decrease in 
tetrahydrobiopterin (BH4) (Zuckerbraun, George, & Gladwin, 2011). As such, drug 
therapies that increase NO bioavailability via either a reduction in cGMP degradation 
(Sildenafil, Tadalafil), or more recently, through cGMP stimulation (Riociguat) have 
either been approved or are in advanced trials.  
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 While work on the ‘classic’ L-arginine-NOS-NO pathway will undoubtedly 
continue, an alternative, NOS-independent mechanism of NO generation has recently 
been discovered (Lundberg et al., 2009; Lundberg, Weitzberg, & Gladwin, 2008). Once 
thought to be inert byproducts of NO production, circulating nitrate and nitrite ions are 
now known to be converted back to NO via anaerobic bacteria in the oral cavity, 
protonation in the stomach and reduction facilitated by hemoglobin, myoglobin and XOR 
(Zuckerbraun et al., 2010). Crucially, it has been demonstrated this alternative pathway is 
oxygen-independent, and the enzymatic reduction of nitrite to NO is upregulated in 
hypoxic conditions (Khatri, Mills, Maskell, Odongerel, & Webb, 2017). Thus, in the 
milieu of PAH, with disrupted NOS signaling and reduced oxygen delivery, manipulation 
of the nitrate-nitrite-NO pathway could be crucial in tackling disease progression and 
providing symptom relief. Fortunately, it has been shown that consumption of dietary 
nitrate can significantly elevate plasma nitrate and nitrite (Lundberg et al., 2009). As 
such, simple, non-pharmacological approaches, such as increased intake of nitrate-rich 
foods may be a useful tool in altering NO signaling and improving vascular function in 
PAH (Figure 2.3). Pre-clinical trials have employed dietary strategies and examined the 
therapeutic effects on animal models of vascular disease. Nitrate and nitrite in drinking 
water reduced RV hypertrophy, RV systolic blood pressure and vascular remodeling in 
hypoxia-induced PH mouse model (Baliga et al., 2012). Additionally, Alef et al. (2011) 
demonstrated that sodium nitrite in drinking water limited the development of intimal 
hyperplasia in a rat model of vascular injury.  
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Finally, although not strictly a dietary approach, nebulized nitrite has been shown 
to reverse RV hypertrophy in a PAH animal model, while also reducing smooth muscle 
cell proliferation in vitro (Zuckerbraun et al., 2010).  
 
Figure 2.3: Pathways of NO generation, adapted from Ataya et al. (2011) 
  
Dietary Nitrate and Exercise 
 While the potential disease mediating benefits of dietary nitrate warrant further 
research, there is a wealth of evidence pointing to its efficacy in improving exercise 
performance (Coggan & Peterson, 2018; A. M. Jones, 2014a, 2014b; A. M. Jones, 
Thompson, Wylie, & Vanhatalo, 2018). Acute and chronic supplementation of dietary 
nitrate has been shown to improve running and cycling performance in healthy subjects, 
however, these findings are not consistent and may depend on the initial training status of 
participants (A. M. Jones et al., 2018). In attempting to explain improvements, several 
mechanistic avenues have been explored. Dietary nitrate has been shown to reduce the 
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oxygen cost of exercise. In other words, after nitrate supplementation, oxygen 
consumption is significantly lower at the same absolute workload, and this has been 
confirmed during moderate and higher intensity exercise (Bailey et al., 2010; Bailey et 
al., 2009; Larsen, Weitzberg, Lundberg, & Ekblom, 2007; Vanhatalo et al., 2010). This 
improved economy of exercise may be due to several mechanisms, including the sparing 
of phosphocreatine and altered ATP cost of muscle power production. Additionally, it has 
been suggested that nitrate supplementation may directly affect mitochondrial action 
either indirectly via reduced respiratory stimulus, or directly by reducing proton leak 
across the mitochondrial membrane (Bailey et al., 2010; Larsen et al., 2011).  Based on 
the above observations, the potential for dietary nitrate supplementation to improve 
exercise performance in PAH may be profound. It has been demonstrated that PAH 
patients have reduced skeletal muscle oxygen uptake and lower VO2max compared to 
healthy individuals, and as such, reducing the oxygen cost of exercise may prove 
beneficial in maintaining submaximal workloads in those that are profoundly exercise 
intolerant.  
 Dietary nitrate has been shown to increase blood flow in both humans and rats. 
Ferguson et al. (2013) directly measured skeletal muscle blood flow during exercise via 
radiolabeled microspheres, and determined that in rats, BRJ supplementation 
significantly increased flow, primarily in type II fibers. Casey, Treichler, Ganger, 
Schneider, and Ueda (2015) supported these findings by measuring forearm blood flow 
via Doppler imaging after BRJ ingestion in young and older adults. During rhythmic 
submaximal forearm contractions, muscle blood flow was increased via compensatory 
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vasodilation in response to hypoxia. As oxygen uptake is dependent in part on blood 
flow, it is suggested this mechanism may directly enhance exercise performance.  
 While early work on dietary nitrate and exercise considered its usefulness in 
longer-duration aerobic activity, recent evidence has shown the benefit of 
supplementation in shorter-duration, predominantly anaerobic efforts. It was recently 
demonstrated that 5 days of dosing with beetroot juice improved power output and 
intermittent cycling performance in team-sport athletes (Wylie et al., 2016). These 
findings were complimented by Thompson et al. (2016), who showed that 5 days of 
beetroot juice supplementation improved sprint-times and distance covered in a sports-
specific high intensity running test. Again however, these findings are not consistent (A. 
M. Jones et al., 2018). Mechanistically, it has been postulated that dietary nitrate may 
upregulate muscle calcium-handling proteins and subsequently, muscle force production. 
Coggan, Leibowitz, Kadkhodayan, et al. (2015) explored the potential benefits of 
dietary nitrate dosing on muscle performance. In a novel approach, a single dose of 
beetroot juice was administered, following which knee extensor function was measured 
via isokinetic dynamometry. Peak knee extensor power at the highest velocity was 
increased by 4% concomitant with a significant rise in breath NO post-BRJ 
supplementation. This work was mirrored by that of Rimer, Peterson, Coggan, and 
Martin (2016) who demonstrated that a single dose of dietary nitrate was sufficient to 
increase very short duration cycling sprints in comparison to controls. These findings are 
important, not least because a single dose approach would likely rule out potential 
changes in post-translational calcium-handling protein levels put forward as a 
mechanistic explanation for improved strength and power. To that end, Whitfield et al. 
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(2017) showed that despite an improvement in muscle power after one week of 
supplementation with beetroot juice, human muscle biopsies showed no increase in 
proteins associated with calcium-handling. Coggan and Peterson (2018) considered this 
phenomenon and postulated several mechanisms for increased contractile function after 
dietary nitrate ingestion. It was argued that nitrosylation of the ryanodine receptor on the 
sarcoplasmic reticulum may be forced open, with a subsequent increase in free calcium. 
An added downstream effect of this free calcium is to activate skeletal muscle myosin 
light chain kinase, which increases calcium sensitivity of contractile apparatus (Coggan 
& Peterson, 2018), potentially improving muscle strength and power. 
 
Dietary Nitrate and Exercise in Disease 
 Several groups have sought to test the effectiveness of dietary nitrate as a means 
of improving exercise capacity in disease states, with one pilot study doing so in PAH 
patients (Henrohn et al., 2018). Ferguson et al. (2016) added to their previous work 
analyzing blood flow during exercise by supplementing a rat model of heart failure after 
myocardial infarction. As was seen in healthy animals, 5 days of nitrate supplementation 
in drinking water significantly elevated plasma nitrate and nitrite, and also increased 
skeletal muscle blood flow during exercise in comparison to those animals supplemented 
with placebo. As a result, this approach was recommended for further study as a novel 
treatment and ergogenic aid in cardiovascular diseases. Exercise capacity after nitrate 
ingestion has also been measured in patients with peripheral artery disease (Kenjale et al., 
2011). Interestingly, a single dose of beetroot juice increased walking time by 17% in 
comparison to those given placebo treatment. Additionally, a trend toward reduction in 
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oxygen cost of exercise was seen at low intensities, similar to that noted previously in 
healthy subjects. Several studies have considered the effects of dietary nitrate on aerobic 
exercise performance in heart failure of various etiologies. Coggan et al. (2018) 
determined that a single dose of dietary nitrate significantly improved VO2peak and time 
to exhaustion in patients with heart failure with reduced ejection fraction (HFrEF), 
concomitant with increases in plasma NO3-, NO2- and breath NO, supporting previous 
work of Kerley et al. (2016) who demonstrated improved walking performance in 
patients with dilated cardiomyopathy after a single NO3- ingestion. However, nine days of 
BRJ consumption did not improve exercise capacity in patients with HFrEF despite 
increases in plasma nitrite post supplementation (D. M. Hirai et al., 2017). In heart failure 
with preserved ejection fraction (HFpEF), it has been shown that a single dose of dietary 
NO3- improved VO2peak and total work performed during a maximal supine cycling 
exercise test (Zamani et al., 2015). In addition to aerobic exercise, the question as to 
muscle strength and power improvements after acute dietary nitrate supplementation has 
been addressed in patients with left heart failure (Coggan, Leibowitz, Spearie, et al., 
2015). Similar to findings in healthy subjects, patients demonstrated a significant 
improvement in muscle power compared to those given placebo treatment. This is not to 
say that patient data is unequivocal. Two trials employing week-long dietary nitrate 
dosing strategy (via beetroot juice and sodium nitrate) in COPD patients elicited no 
improvements in walk distance, oxygen consumption and cycling endurance time, and as 
such, work exploring optimal dosing strategies, drug interactions and exercise test 
sensitivity is warranted (A. M. Jones et al., 2018).  
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 When considering the aforementioned reasons behind exercise intolerance in 
PAH, and the potential mechanisms of action by which dietary nitrate may improve 
exercise performance (Figure 2.4), testing its viability in PAH patients is justified. One 
recent trial sought to determine the effectiveness of two weeks of BRJ supplementation 
on disease markers and exercise performance in 15 group I functional class PAH patients. 
It was noted that those treated with beetroot juice tended to have a higher peak power 
output/peak oxygen consumption ratio in the 6-minute walk test, as well as a tendency for 
improved right ventricular function via echocardiography. It was suggested that those 
who responded most favorably to the supplementation (via plasma nitrate/nitrite 
measures) showed the greatest exercise responses (Henrohn et al., 2018), adding a 
potential consideration when determining the effectiveness of dietary nitrate in 
populations with cardiovascular disease.  
 
 
Figure 2.4: Potential mechanisms by which dietary nitrate may improve exercise 
performance in PAH. 
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Summary 
 Review of the pertinent literature has described the complex an interrelated 
pathophysiology of PAH. The maladaptations described in the heart, lungs and skeletal 
muscle can be directly connected to the severe exercise intolerance suffered by PAH 
patients. It has been demonstrated that further mechanistic work on exercise 
pathophysiology is warranted, with specific emphasis on how skeletal muscle 
abnormalities may play a role in reduced exercise performance. To date, it has not been 
directly determined if skeletal muscle blood flow is reduced in PAH during exercise, and 
a full characterization of this phenomenon would be useful in developing a fuller 
understanding of the disease. Additionally, the search for alternative therapies has pushed 
exercise into the forefront of PAH management. As such, novel strategies to improve 
exercise tolerance are being considered. One such strategy is the supplementation of 
dietary nitrate, which has been shown to improve exercise performance in health and 
disease. Moreover, the proposed mechanisms of action seem to suggest that PAH may be 
an ideal condition in which to consider its effectiveness. Taken together, the data justifies 
the proposed work herein, with the ultimate aim of improving quality of life for PAH 
patients.  
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Chapter Three: Methodology 
Introduction 
This study aimed to characterize skeletal muscle blood flow at rest and during 
exercise in an animal model of PAH, and to interrogate the effectiveness of acute dietary 
nitrate supplementation in improving skeletal muscle blood flow and metabolism during 
exercise. Mechanistic analyses were complimented by functional testing to determine if 
dietary nitrate supplementation could impact exercise performance in PAH. The previous 
chapter outlined a review of the literature in this area, and provided rationale for the 
following experimental design.  
  
Research Design/Timeline 
A randomized, between-animal experimental design provided the basis for 
characterizing skeletal muscle blood flow and determining the effectiveness of dietary 
nitrate supplementation in impacting skeletal muscle blood flow and exercise capacity in 
healthy and PAH afflicted animals. The study employed four groups of animals across 
three specific aims: Group 1 – PH + BRJ; Group 2 – PH + PL; Group 3 – CON + BRJ; 
Group 4 – CON + PL.  
Using a counterbalanced, placebo-controlled approach, each rat carried out 
functional exercise testing (VO2max, 12-hour voluntary wheel run, grip-strength test) pre 
and post PAH induction under both BRJ and placebo supplementation, with control 
groups tested on the same timeline. After post-disease functional testing, blood flow 
analysis (via the administration of fluorescent microspheres) was carried out during 
exercise and at rest for all groups, under either BRJ or placebo conditions, followed by 
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invasive hemodynamics, euthanasia and tissue harvest. Tissues were processed to 
determine dietary nitrate dosing effectiveness, skeletal muscle blood flow and 
capillarization via immunofluorescent analysis. Study design and timeline are 
summarized in Figure 3.1.   
 
  
  
4
6
 
 
Figure 3.1: Research design/timeline 
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Methods for Specific Aim 1 
Animal Experimental Model 
Male Sprague Dawley rats (~200g) were randomly assigned into four groups as 
previously described. PAH rats were injected with monocrotaline (MCT – 60mg/kg, s.q, 
in sterile PBS vehicle, Sigma Aldrich). MCT is a plant-based toxic alkaloid that has been 
recognized as producing a pulmonary hypertensive phenotype in various species for half 
a century (Kay, Harris, & Heath, 1967). Once metabolized by mixed-function oxidases in 
the liver, MCT is known to induce vascular injury. While the exact mechanisms by which 
the initial vascular insult progresses to a PH phenotype are unknown, it is speculated to 
be a result of direct endothelial remodeling and/or accumulation of mononuclear 
inflammatory cells into the vascular adventitia, prior to RV hypertrophy and increased 
pulmonary arterial pressures (Stenmark, Meyrick, Galie, Mooi, & McMurtry, 2009). 
Dose response and timeline data have been published, with doses of 30-40mg/kg 
resulting in ‘compensated’ RV hypertrophy with increased RVSP and the maintenance of 
cardiac output. Higher doses of 60-80mg/kg has been shown to elevate pulmonary 
pressures to a greater extent, resulting increased RV wall stress, reduced ejection fraction, 
and ultimately pump failure at ~4wks post-MCT injection (Hessel, Steendijk, den Adel, 
Schutte, & van der Laarse, 2006). While the MCT model is well established and 
technically simple, it has limitations. It has been considered an inflammatory-driven 
model of disease, as opposed to alternative angioproliferative and vascular lesion-
forming models such as that brought about by alternative methods, that may closer mimic 
PH phenotype in patients (Gomez-Arroyo et al., 2012). However, it continues to be used 
as a model of PH in a wide variety of animal studies, driven primarily by its reflection of 
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vascular injury and cardiac dysfunction as is seen in PAH patients. The timeline herein 
employed a timeframe of four weeks post MCT injection as the time point for terminal 
blood flow experiments, hence, a severe PH model is under investigation. Control rats 
were injected with s.q. vehicle solution (PBS). All animals were housed in pairs in the 
Indiana University animal facility and fed standard rat chow and water ad libitum. The 
rats were maintained at an ambient temperature of 21–24°C with a 12 h–12 h dark–light 
cycle.  
 Power Analysis and Group Determination 
Limited data exists regarding skeletal muscle blood flow at rest and during 
exercise in a PH rat model, however our lab has previously determined normative data 
for a major outcome variable in this study (%change in VO2max pre-post disease, Aim 
2), which can be used to determine group sizes as follows: mu 1=18, mu 2=3, sigma=11, 
alpha=0.5, desired power =0.8, calculated sample size = 9 each group. As such, the 
following groups were defined: Group 1 – PH + BRJ, n = 9; Group 2 – PH + PL, n = 9; 
Group 3 – CON + BRJ, n = 9 ; Group 4 – CON + PL, n = 9 
 
Exercise 
Treadmill Familiarization  
As running is a skill activity for rats, familiarization to the rodent motorized 
treadmill that permits metabolic measurements via indirect calorimetry (Columbus 
Instruments, Columbus, OH) was carried out for 4 days before exercise testing. The 
familiarization protocol involved 4 x 5 minute runs that gradually increased treadmill 
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speed (8m/min-12m/min) and incline (0 to 15 degrees). These inclines and speeds are 
similar to those experienced during initial maximal aerobic testing.  Familiarization runs 
were kept at this short time-frame to minimize chronic training effects before baseline 
testing. A mild electric stimulus at the back of the treadmill chamber promoted the 
learning of running behavior, and the ability of the rat to run successfully was 
documented through this familiarization period. ‘Cueing’, including the use of verbal 
encouragement, treadmill lane taps and group-running were used to promote consistent 
running toward the front of the treadmill belt. If a rat contacted the stimulus three 
consecutive times without the ability to recover to the front of the treadmill belt, the 
familiarization session was terminated. Written notes were taken to document each rats’ 
ability to run successfully, ensuring careful monitoring throughout. 
 
Maximal Oxygen Consumption (VO2max) Testing 
To measure exercising blood flow, all rats ran at 50% of their VO2max as 
determined by their final VO2max test on days 29/30 (Aim 1). In addition, VO2max was 
used as a measure of functional capacity in pre and post disease testing, with either BRJ 
or placebo supplementation. (Aims 2 and 3). Gas analyzer calibrations were conducted 
before testing using standardized gas mixtures (Praxair, Indianapolis, IN, USA). Baseline 
VO2 was monitored for 3-5 minutes until stabilization, and this was recorded as “resting 
VO2”. For determination of VO2max, an incremental treadmill running protocol was 
employed, modified from (Kemi, Loennechen, Wisloff, & Ellingsen, 2002) using 3 
minute stages as follows: 8 m/minute at 5 degrees (warm up), 8 m/minute at 15 degrees, 
9.8 m/minute at 15 degrees, 11.6 m/minute at 15 degrees, etc., with the speed continuing 
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to increase by 1.8 m/minute every three minutes until test completion. VO2 was measured 
at 20 second intervals throughout. The test was modified from Kemi et al. (2002), who 
suggest an incline of 25 degrees, for several reasons. First, it was determined that MCT 
rats’ ability to run at such an incline was inconsistent, and the modified protocol resulted 
in a test that was more easily tolerated. Importantly, because blood flow measures were 
carried out at a known percentage of VO2, it was important these conditions were 
replicated in terminal testing. Crucially, it is well established that acute responses to 
exercise in the rat, including muscle activation patterns are dependent on incline (Gillis & 
Biewener, 2002; Lynn, Talbot, & Morgan, 1998), and as such, treadmill incline would 
have to be the same between MCT and CON rats to carry out a meaningful comparison 
The test was terminated when VO2 plateaued despite increasing workload, or if the rat 
was unable to maintain running after 3 consecutive electrical stimuli without recovery to 
the front of the treadmill belt. The highest VO2 measured in the minute following test 
completion was recorded as VO2max and expressed relative to body weight (ml/kg/hr). 
Respiratory exchange ratio (RER, VO2/VCO2) was recorded concomitantly during 
running. Following testing, rats were immediately removed from treadmill apparatus and 
placed back into their cage.  
 
Echocardiography 
To characterize disease phenotype, echocardiography was performed one day 
before terminal blood flow testing. Rats were anesthetized with 5% isoflurane in an 
induction box and then placed on the heated platform with a nose cone and maintained at 
1-2%. The hair was clipped over the chest and fine hair removed using a depilatory 
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cream.  The skin was cleaned with wet gauze squares. Ultrasonic gel was place over the 
chest for the echo procedure and an ultrasonic probe of approximately 6 cm by 8 cm was 
placed in contact with the gel. After the images are collected the chest was cleansed with 
gauze squares and the rat was placed into a heated cage to recover. All images were 
obtained by a blinded sonographer. LV/RV wall thicknesses, LV/RV mass, ejection 
fraction, stroke volume, RVSP and cardiac output (derived from RV outflow tract 
diameter and velocity time integral), which is expressed relative to body mass as cardiac 
index, were all reported by the sonographer.  
 
Blood Flow Measurement 
Blood flow to working skeletal muscle was measured using fluorescent 
microspheres injected during and after moderate intensity running (50% VO2max) for PH 
and healthy control rats. This ‘gold-standard’ measure of blood flow was pioneered 
initially by Heymann, Payne, Hoffman, and Rudolph (1977) and Rudolph and Heymann 
(1967), who determined that injecting radio-labeled microspheres into the arterial 
circulation, and subsequently measuring radioactivity in specific harvested organs can 
result in extremely accurate measurements blood flow. This was further developed 
specifically for fluorescent-labeled spheres by Glenny, Bernard, and Brinkley (1993) 
Prinzen and Glenny (1994), driven in part by the increased legislation and cost of 
handling radioactive materials. This method relies on the fact that fluorescent 
microspheres injected via arterial catheters embed in the microcirculation of organs, and 
subsequent spectrometric measurements of those tissues accurately represents blood flow 
at the time of injection. Importantly, to determine flow most accurately, the ‘reference 
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line’ technique should be employed (Glenny et al., 1993). Here, measurement of regional 
perfusion is calculated as a fraction of total cardiac output, measured by capturing the 
fluorescence in blood sampled in a separate cannula at the time of microspheres injection 
in the arterial line (Ishise, Pegram, Yamamoto, Kitamura, & Frohlich, 1980). This 
method therefore requires animals to be cannulated with two separate lines, one being 
used to deliver microspheres, and the other used to collect reference line blood samples. 
 
  Surgical Preparation 
 On the day of experimentation, rats were surgically prepared for blood flow 
analysis as outlined previously.  Rats were anesthetized by inhaled isoflurane and then 
orotracheally intubated with a catheter (appx. 14 gauge). Rats were mechanically 
ventilated using a tidal volume of 6 ml/kg and a rate of 65-70 breaths/min.  End 
expiratory pressures were at 3-4 cmH2O by a water overflow on the expiratory limb of 
the ventilator. Airway pressures were monitored continuously during surgeries. The rats 
were placed on a servo-controlled heated tray that maintains animal temperature at 37º C. 
Animals were shaved (total abdominal, thoracic surfaces), and the skin cleansed with 
Betadine and ETOH. The animal was fixed to the operating table with adhesive tape and 
covered with sterile drape with a hole allowing access to the surgical area. The animal 
was given carprofen (5mg/kg: 0.1-0.5ml,SQ) before surgery. The right carotid artery and 
caudal (tail) artery were cannulated via cutdowns through small skin incisions. Arterial 
and airway pressures were measured continuously. Normal saline boluses (10 ml/kg) 
were given at the beginning of the procedure to replace blood loss from surgery, blood 
sampling, and ongoing insensible losses during surgery. After placement, tubing was 
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tunneled subcutaneously between the scapulae, and tied in with approx. 10 inches of 
external line access for microsphere delivery and reference blood sampling in carotid and 
caudal lines. Incisions were closed using silk suture for muscle layers and monofilament 
suture for skin. Total time for surgery was approximately one hour. Following surgery, 
animals were placed back in the cage for recovery, and in preparation for exercising and 
resting blood flow measures.  
 
Resting and Exercising Microsphere Infusion 
After a minimum of one-hour recovery post-surgery, fluorescent microspheres 
were prepared for infusion by sonicating for >5 mins and vigorously vortexing for > 1 
minute. The caudal artery line was flushed with 0.5ml saline to encourage effective 
bleed-back of reference blood. Running was initiated at moderate intensity as determined 
by calculating 50% VO2max from the animal’s latest VO2max test, using the Karvonen 
formula as follows: 
50% VO2max = ([VO2max – VO2rest x .5]) + VO2rest 
 The calculated VO2max was then referenced to the latest VO2max testing data, 
and the stage at which this VO2 was reached was used as the intensity for running. After 
3 minutes of running at the predetermined intensity, fluorescent microspheres (n= approx. 
400,000, Red, 580/620, Molecular Probes) were injected over 10 s into the carotid 
cannula. The line was subsequently flushed with 0.5ml heparinized saline to ensure all 
spheres were successfully injected. 10 s prior to microsphere infusion, collection of a 
reference blood sample from the caudal cannula was begun using a motorized syringe 
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withdrawal pump (Kent Scientific, CT, USA). Blood was collected for 60 seconds at a 
constant rate of 1 ml/min. Following exercise measures, the rat rested for 1 hour before 
determination of resting blood flow. At this time, a second microsphere infusion of a 
different color (n=approx. 400,000, Yellow-Green, 500/545, Molecular Probes) was 
performed in the same manner. It has previously been shown that rats familiarized to 
exercise may exhibit an anticipatory response to exercise that specifically increases 
skeletal muscle blood flow (Armstrong, Hayes, & Delp, 1989), hence exercising 
measures were carried out, and after a 1 hour rest period, resting measures were taken 
using the same protocol.  
 
Exercising and Resting Metabolism 
To determine the effects of PAH induction on resting and exercise metabolism 
and/or a potential link between blood flow and metabolism (Aim 1), as well as to 
investigate the effectiveness of BRJ in altering metabolic control (Aim 2), plasma lactate 
was measured using a small sample of arterial blood from the caudal line used for 
reference blood sampling.  It is well established that non-oxidative means of ATP 
synthesis results in the accumulation of lactate and hydrogen ions in the blood, 
representing a switch from aerobic to anaerobic metabolism (Kenney, Wilmore, & 
Costill, 2012), hence its measurement can give an indication as to metabolic control and 
exercise capacity. Approximately 10 l of blood was withdrawn after the reference blood 
sample and immediately transferred to a hand-held, portable lactate analyzer (Lactate 
Pro, Sports Resource Group, USA), previously used to measure blood lactate in 
exercising rats (Kato, Kurakane, Nishina, Park, & Chang, 2013; Lu et al., 1996). A small 
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drop of whole blood was placed on a lactate test strip (Sports Resource Group, USA), 
with results presented on the analyzer 13 seconds after initial contact.  
 
Invasive Hemodynamics 
Immediately after resting blood flow and lactate measures, rats were 
anaesthetized by inhalation of isofluorane-O2 mixture (5%), orotracheally intubated and 
mechanically ventilated under isofluorane maintenance (2%). The left carotid artery was 
cannulated with PE-50 tubing and the right internal jugular vein with a 2F Millar catheter 
(Millar Instruments, Houston, TX, USA). Surgery was performed on a servo-controlled 
heated tray that maintained animal temperature at 37°C. Recordings of pulmonary and 
systemic pressures were achieved within 30 minutes following transfer out of the 
treadmill chamber. Right ventricular systolic pressure (RVSP) and mean arterial pressure 
(MAP) were assessed in room air and recorded simultaneously.   
 
Tissue Processing 
Immediately after hemodynamic measurements, rats were euthanized under 
anesthesia (5% isofluorance-O2 mixture) via exsanguination and bilateral 
pneumonectomy as a secondary means of euthanasia which also allowed for immediate 
access to the diaphragm and heart muscles. Right ventricular hypertrophy was assessed 
by measuring the Fulton index [weight of the RV divided by weight of the left ventricle 
plus septum (S); RV/(LV + S)]. Sections of RV, LV, liver, kidney and muscle 
(diaphragm, biceps femoris, semitendinosus, extensor digitorum longus, tibialis anterior, 
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gastrocnemius, soleus, rectus femoris, vastus lateralis) were then snap frozen for further 
biochemical analysis. Muscle samples from the same muscle groups were collected from 
the contralateral leg for blood flow quantification. Muscles were weighed and placed in 
5% ethanoic potassium hydroxide for 48 hours for tissue degradation. Samples were 
regularly vortexed to ensure full degradation. Reference blood collected during exercise 
and at rest were processed in the same fashion. After degradation, samples were reverse-
filtered through 5μm polyamide mesh filters (Sterlitech, WA, USA). Each filter was 
carefully placed into a 1.5 ml microcentrifuge tube (Thermo Fisher, MA, USA) and 1 mL 
of cellosolve acetate (2-ethoxyethyl acetate, 98%, Sigma Aldrich) was added to each of 
the tubes to degrade microspheres and expose the fluorescence. At 1 h tubes were 
vortexed to ensure maximum exposure to cellosolve acetate. This was repeated at 2 h. 
100 μL samples from each tube were then loaded in duplicate into a 96-well plate in 
preparation for spectroscopic analysis (Figure 3.2).  
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Figure 3.2: Plate set-up for spectroscopic analysis 
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Blood Flow Quantification 
  All fluorescence measurements were made using the SpectraMax i3x microplate 
reader (Molecular Devices, CA). Red fluorescence (representing exercising flow) was 
measured using an excitation of 580 nm and an emission of 620 nm, and yellow-green 
(representing resting flow) at an excitation of 500 nm and an emission of 545 nm. Tissue 
blood flow was calculated using the reference blood sample with the following equation 
(Glenny et al., 1993; Vescovo et al., 1998).  
Flow (ml/min) = (fluorescence of sample) x (reference line withdrawal rate) 
 
Blood flow units are calculated and presented as ml•min-1•g-1 of tissue by dividing 
calculated flow by the recorded muscle weight at time of harvest. Bilateral kidney flow 
was used as a measure of adequate microsphere mixing and subsequent uniform systemic 
blood flow in vivo (Ferguson et al., 2013), with a discrepancy of  >20% in blood flow 
across right and left kidneys resulting in that animal being disregarded from blood flow 
analysis. Figure 3.3 depicts the microsphere/blood flow analysis protocol, adapted from 
Aref, Akans, and Allen (2017). 
 
fluorescence of reference blood 
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Figure 3.3: Microsphere/blood flow analysis protocol 
 
 
Capillarization 
To determine if muscle capillarization differed between MCT and CON rats, 
immunofluorescent staining of frozen muscle sections was carried out. The midsection of 
frozen muscles was cut, embedded in OCT (Fisher Scientific, USA) and placed in -80°C 
in preparation for tissue sectioning. Muscles were sectioned at 8µm using a cryostat 
(Reichert-Jung Frigocut 2800) at -20°C and mounted on Superfrost Plus Microscope 
Slides (Fisher Scientific, USA). Slides were submerged in 2% paraformaldehyde for 10 
minutes.  They were subsequently air-dried and stored at –80°C in preparation for 
staining. After three washes in phosphor-buffered saline with Tween (PBS-T, Fisher 
Scientific, USA) sections were incubated for 48hrs at 4°C with an antibody cocktail 
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containing 1:500 dilution Wheat Germ Agglutinin (W6748 WGA-oregon green 488 
conjugate 5mg, Thermo Fisher, USA), 1:75 dilution lectin (isolectin GS-IB4 alexaFluor 
594 conjugate, Thermo Fisher, USA) in Tris Buffered Saline (TBS) vehicle (Thermo 
Fisher, USA). Negative controls were processed similarly, with antibodies replaced by 
incubation in TBS only. Slides were washed three times in PBS-T, after which coverslips 
containing DAPI ProLong Gold (Fisher Scientific, USA) for nuclei staining were 
mounted to slides and fixed using Biotium Covereslip Sealant (Biotium, CA, USA). 
Tissue sections were imaged using a Nikon Eclipse Ti2 inverted fluorescence microscope 
(NY, USA). Three different fields were imaged in each tissue section (9 per muscle 
sample). Green, red and blue images were taken at their optimal exposure times by a 
technician blinded to group assignments, and exported to ImageJ (NIH, USA) for further 
analysis.  
 
Methods for Specific Aim 2  
 Dietary Nitrate Dosing 
Both acute and chronic dietary nitrate dosing approaches have been employed in 
an attempt to investigate the effectiveness of supplementation on exercise performance 
(A. M. Jones et al., 2018). Depending on the outcome of interest, both acute (single dose) 
and chronic (multiple doses) have resulted in improved exercise performance, however, 
only a chronic dose has been used to specifically interrogate the effectiveness of BRJ in 
augmenting blood flow in rats (Ferguson et al., 2013). This poses a standardization 
problem in regards to dosing BRJ and subsequent exercise performance, as it cannot be 
known when the last intake of nitrate took place. As such, an acute, measured nitrate dose 
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may be required. A single dose of BRJ has been shown to improve exercise economy 
(Hoon et al., 2014; Vanhatalo et al., 2010; Wylie et al., 2013) and muscular power 
(Coggan, Leibowitz, Kadkhodayan, et al., 2015; Coggan, Leibowitz, Spearie, et al., 2015; 
Rimer et al., 2016) in healthy and patient populations, hence this dosing strategy warrants 
further research as a potential tool to alter blood flow and exercise performance in a PH 
animal model. Additionally, the translational value of a single dose of BRJ may be 
significant. If a patient with PAH were to gain an exercise advantage after ingestion of 
BRJ prior to an exercise bout, it may provide an alternative strategy to combat the 
exercise intolerance associated with the disease and improve likelihood of the patient 
achieving minimum threshold for positive exercise adaptations . It has been demonstrated 
that increasing exercise intensity, for both resistance training (Campos et al., 2002; Fry, 
2004) and aerobic exercise (McNicol, O'Brien, Paton, & Knez, 2009; Seiler, Joranson, 
Olesen, & Hetlelid, 2013) is an important factor in mediating positive physiological 
adaptations, and as such, an increase in workload achieved during exercise may be 
critical for patients with PAH seeking to maximize the previously outlined benefits of 
exercise.  
This strategy, while novel, poses a methodological problem in supplementing rats. 
While chronic dosing can be achieved by mixing BRJ in drinking water, there is no way 
to ensure an adequate acute dose prior to exercise if it were to be ingested ad libitum. To 
combat this problem, rats were gavaged with a measured dose of BRJ prior to functional 
exercise and blood flow testing, a common technique used to tests the pharmacokinetics 
of ingested compounds in rat models (A. P. Brown, Dinger, & Levine, 2000). Rats were 
anesthetized by inhaled isoflurane at 5% in a sealed chamber, before being quickly hung 
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on a specialized cage allowing access to the oral cavity. A soft-tipped hemostat was 
placed around the rat’s tongue, moving it laterally for direct access to the esophagus. 
After the soft needle was inserted, the liquid supplement was slowly and consistently 
administered from a clear syringe until empty. The hemostats were then removed and the 
rat placed back in the cage. The total time of gavage was ~20 seconds, ensuring the rat 
did not wake during the procedure. Preliminary work was performed to determine time-
course of plasma nitrate/nitrite increases after gavage. This data (see Appendix A) 
indicated that ideal time to dose before exercise was between 2-3 hours. This work 
allowed for optimization of supplementation timing prior to exercise, and was 
subsequently used prior to functional testing and blood flow analysis.  
 
 Measurement of Plasma Nitrate/Nitrite 
An additional 300l of blood was taken from the reference line during blood flow 
studies and processed for measurement of plasma nitrate/nitrite via High Performance 
Liquid Chromatography (HPLC, Eicom, ENO-30). This method involves post-column 
derivatization of nitrite with 2,3-diaminonaphthalene (DAN), forming compounds that 
are absorbed in the visible light range (Troutman, Gallardo, Brown, & Coggan, 2018), 
resulting in highly sensitive measures of nitrate and nitrite in biological samples.  Upon 
withdrawal, whole blood was immediately centrifuged for 10 minutes at 10,000 rpm 
(Eppendorf, Hamburg, Germany), with the resulting plasma supernatant aliquoted into 
1ml microcentrifuge tube (Thermo Fisher, MA, USA) and placed in -80°C in preparation 
for HPLC analysis. Plasma was thawed on wet ice, and mixed with equal parts HPLC-
grade methanol (Fisher Scientific, USA) and centrifuged for 10 minutes at 10,000 rpm. 
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The supernatant was removed and aliquoted into 1ml microcentrifuge tubes. 10l of the 
plasma/methanol solution was manually injected into the HPLC machine per user 
instructions. Chromatograms indicating ‘peaks’ of nitrate and nitrite in samples were then 
integrated and compared against known nitrate and nitrite standards to quantify levels in 
injected samples.   
 
 Measurement of Muscle Nitrate/Nitrite 
A novel method using HPLC to quantify nitrate and nitrite levels in muscle 
samples has recently been developed (Troutman et al., 2018). This gives the advantage of 
comparing plasma and muscle nitrate/nitrite levels post supplementation in the same 
animal. Additionally, the effectiveness of dietary nitrate supplementation in increasing 
nitrate and nitrite in multiple tissues can be interrogated. This is crucial, as it has been 
shown that in rodents, skeletal muscle may be a major NO reserve via the outlined NO3-
NO2--NO pathway (Piknova et al., 2015). Frozen muscle samples (~40mg) were 
pulverized at liquid N2 temperature in a stainless steel tissue pulverizer (Bessman Tissue 
Pulverizer, Thermo Fischer Scientific). The muscle tissue was then transferred into a pre-
weighed microcentrifuge tube containing 50l ethanol, 0.5% triton X-100 and 0.1 mmol/l 
oxypurinol, a solution found to yield highest NO2-/NO3- values and strongest 
reproducibility across samples (Troutman et al., 2018). After vortexing, samples were 
placed on ice for >30 min, reweighed to determine the amount of tissue added, then 
centrifuged. The supernatant was removed and aliquoted into 1ml microcentrifuge tubes, 
before HPLC analysis as was done for plasma samples.  
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Methods for Specific Aim 3  
To determine the effects of PAH induction on exercise capacity, as well as the 
effectiveness of acute dietary nitrate dosing in improving functional performance, three 
counterbalanced exercise tests were carried out pre and post disease and ~2 hours after 
BRJ or PL supplementation.  
 Maximal Oxygen Consumption (VO2max) Testing 
As described under Aim 1. 
Voluntary Wheel Running 
Voluntary wheel running is an exercise modality that has been used successfully 
in rats and mice, with animals displaying an inherent drive to run when given access to 
activity wheels.  Rats voluntarily ran on an activity wheel (Lafayette Instruments, Model 
80850S Scurry Rat Activity Wheel); with wheel revolutions monitored by 86115 Scurry 
Sensor/Counter, 86130 Interface and 86165 Scurry Software, connected to a computer 
interface for complete data collection (3 second sample rate), analysis and charting. 
Voluntary running distance (meters) and maximum speed achieved was measured over 
the 12-hour dark cycle, with gavage taking place 2-3 hours prior to the dark cycle 
beginning.  
 Grip Strength 
Voluntary grip strength was measured using specialized apparatus for the rat 
(Harvard Apparatus, MA, USA). Rats were held from the base of the tail and gently 
lowered until all four paws grasped the grid of testing apparatus. From a horizontal 
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position, the tail was gently and steadily pulled back until the grip was voluntarily 
released. The maximal force achieved by the animal was recorded (grams), with each 
animal will performing 3 repetitions, with a minimum of 1-minute rest between each trial 
(Ling, Authier, Balayssac, Eschalier, & Coudore, 2007).  
 
Statistical analysis 
 Statistical analyses were carried out using GraphPad Prism 7.0 (San Diego, CA, 
USA). Data are presented as means ± SE. Differences at α level of 0.05 (P < 0.05) were 
considered statistically significant. In addition to analyzing blood flow measured within 
each harvested skeletal muscle, a ‘compiled blood flow’ variable was also created by 
averaging resting flow and separate exercising flow in individual muscles for each rat. 
Analysis of variance (ANOVA) was carried out by group assignment for the following 
measurements: resting and exercising blood flow, Fulton Index, stroke volume, cardiac 
output, cardiac index, RVSP, and plasma and skeletal muscle nitrate and nitrite. ANOVA 
by group assignment with repeated measures was performed for the following within-rat 
serial measurements: blood flow rest and exercise, blood lactate rest and exercise, body 
mass pre-MCT and 3 wks post-MCT, , VO2max pre-MCT and 3 wks post-MCT, VO2max 
BRJ trial and placebo trial, grip strength pre-MCT and 3 wks post-MCT, grip strength 
BRJ trial and placebo trial, voluntary running distance pre-MCT and 3 wks post-MCT, 
and running distance BRJ trial and placebo trial.  Post-hoc analysis to determine 
individual group differences was performed where appropriate using Tukey’s multiple 
comparison model. Pearson product correlations were used to determine relationships 
between blood flow, plasma/muscle nitrate and metabolic/disease measures.  
 
  65    
Chapter Four: Results 
Animal Attrition and Final Numbers 
A total of n=57 rats were used during data collection, which began 2/13/18 and 
ended 5/14/19. n=7 rats died during gavage procedures (2 in pre-testing, 5 post-testing), 
n=4 rats died of natural causes post MCT injection. n=46 rats carried out terminal blood 
flow testing as outlined, however, n=9 did not demonstrate sufficient kidney blood flow 
to include the data in blood flow analysis. Final groups for terminal testing were: 
CON+BRJ n=8, CON+PL n=9, MCT+PL n=9, MCT+BRJ, n=9. 
 
Aim 1 
PH Phenotype 
For phenotype characterization, MCT (n=11-21) rats were compared to CON 
(n=16-22) regardless of the final experimental condition (i.e. acute dosing of either BRJ 
or PL for blood flow analysis). Four weeks after MCT injection, rats showed a PH 
phenotype (Figure 4.1) as demonstrated by an increased Fulton Index (0.65 ± 0.043 vs. 
0.29 ± 0.011, p=<0.001), larger RV thickness (2.25mm ± 0.13 vs. 1.63mm ± 0.12, 
p=0.001) and increased RVSP (52.27mmHg ± 4.7 vs. 24.25mmHg ± 1.59, p= p=<0.001). 
Echocardiographic measurement indicated a significantly reduced stroke volume 
(218.3uL ± 13.18 vs. 264.3uL ± 10.82, p=0.011), cardiac output (67.46ml/min ± 4.333 
vs. 87.43ml/min ± 3.588, p=0.001), cardiac index (0.19ml/min/kg ± 0.01 vs. 
0.22ml/min/kg ± 0.01, p=0.008). Significantly reduced pulmonary acceleration time 
(PAT, 26.14 ± 1.296 vs. 32.39 ± 1.232, p=0.01), pulmonary artery velocity time interval 
(VTI, 39.62 ± 2.601 vs. 49.67 ± 2.018, p=0.04), and significantly increased total 
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pulmonary resistance index (TPRi 178.4 ± 33.4 vs. 114.4 ± 9.96, p=0.04) compared to 
CON where also identified (Table 4.1). 
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 CON (n=14-18) MCT  (n=16-17) 
Pulm. Acceleration Time (PAT) 32.39 ± 1.232 26.14 ± 1.296 
Pulm. Artery VTI  49.67 ± 2.018 39.62 ± 2.601 
TPRi (RVSP/CI)  114.4 ± 9.96 178.4 ± 33.4 
Table 4.1: Echocardiographic parameters between CON and MCT 
Body mass (Figure 4.2) was not different between groups pre MCT/vehicle 
injection (215.2g ± 8.3, n=18 vs. 232.3g ± 7.5, n=21), however, at harvest MCT rats were 
significantly lighter than their CON counterparts (331.8g ± 11.6, n=15 vs. 400.3g ± 9.4, 
n=17). 
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Figure 4.2: Body mass pre-injection and at harvest 
 
Skeletal Muscle Blood Flow 
The fluorescent microsphere technique was used to directly measure blood flow at 
rest and during moderate intensity exercise. Briefly, a known quantity (400,000) of red 
(exercise) and yellow (rest) microspheres were injected into the aortic arch, during which 
time reference blood was drawn from the caudal artery. Subsequent tissue degradation 
and spectrographic measurement of individual muscles reliably determined tissue blood 
flow in each condition. For the purpose of testing hypothesis 1 (that MCT blood flow is 
reduced) analysis will initially show a comparison of all MCT (n=13-17) against all CON 
  ** 
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(n=12-15) regardless of whether a single dose of BRJ or PL was administered in the 
terminal experiments, since subsequent analyses (to be detailed in Aim 2) indicated no 
effect of BRJ. For completeness, data showing a comparison between MCT (n=6-8) and 
CON (n=6-8) receiving only PL in their terminal experiment are also included in the 
following analyses.  
 
 
Resting Flow  
 
Table 4.2 compares resting blood flow in muscle tissue between CON and MCT 
rats. Blood flow in the gastrocnemius (p=0.04) and tibialis anterior (p=0.009) were 
significantly lower in MCT, with flow significantly increased (p=>0.001) in the 
diaphragm of the same group (Figure 4.3).  
 
Muscle 
Resting Blood Flow (ml/min-1/g-1) 
         CON (n=13-17)                         MCT (n=12-15) 
 
p-value 
Gastrocnemius 0.352 ± 0.05 0.228 ± 0.03* 0.04 
Rectus femoris 0.405 ± 0.07 0.303 ± 0.05 0.22 
Biceps femoris 0.177 ± 0.025 0.14 ± 0.02 0.28 
EDL 0.276 ± 0.054 0.207 ± 0.04 0.33 
Tibialis anterior 0.329 ± 0.05 0.178 ± 0.02** 0.009 
Vastus lateralis 0.214 ± 0.03 0.157 ± 0.02 0.11 
Soleus 0.897 ± 0.20 0.883 ± 0.10 0.95 
Semitendinosus 0.349 ± 0.08 0.255 ± 0.054 0.34 
Diaphragm 1.114 ± 0.064 2.09 ± 0.22** <0.001 
Table 4.2 Resting muscle blood flow 
 
 
Figure 4.3: Resting blood flow in gastrocnemius, tibialis anterior and diaphragm 
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Exercising Flow 
 
Table 4.3 compares blood flow during moderate intensity exercise in muscle 
tissue between CON and MCT rats. Blood flow in all muscles was significantly lower in 
MCT vs. CON (Figure 4.4), other than diaphragm, which tended to be increased in MCT 
vs. CON (p=0.074).  
 
Muscle 
Exercising Blood Flow (ml/min-1/g-1) 
     CON (n=16-17)           MCT (n=12-16) 
 
p-value 
Gastrocnemius 2.084 ± 0.33 1.105 ± 0.21* 0.015 
Rectus femoris 4.013 ± 0.94 1.354 ± 0.26** 0.009 
Biceps femoris 1.003 ± 0.16 0.515 ± 0.11* 0.016 
EDL 1.495 ± 0.37 0.4888 ± 0.06* 0.012 
Tibialis anterior 2.235 ± 0.59 0.7105 ± 0.073** 0.007 
Vastus lateralis 2.208 ± 0.67 0.4336 ± 0.085* 0.014 
Soleus 2.828 ± 0.42 1.409 ± 0.27** 0.007 
Semitendinosus 1.235 ± 0.20 0.7569 ± 0.12* 0.047 
Diaphragm 1.597 ± 0.20 2.248 ± 0.26 0.074 
Table 4.3: Exercising muscle blood flow 
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Figure 4.4: Exercising blood flow in all muscles 
 
Change in Blood Flow from Rest to Exercise 
 
Table 4.4 compares change in blood flow from rest to exercise in MCT and CON 
rats. Blood flow from rest to exercise conditions was significantly greater in CON rats in 
the gastrocnemius, rectus femoris, tibialis anterior, vastus lateralis and soleus muscle 
groups, with a tendency for greater change in biceps femoris (p=0.09) and EDL 
(p=0.053). Figure 4.5 highlights how blood flow changes from rest to exercise for MCT 
and CON rats In this figure, absolute blood flow at rest and exercise (where each line 
represents one rat) is depicted, and to the right the bar graph represents group mean±SE 
of absolute change in blood flow from rest to exercise calculated for each rat. 
 
Muscle 
Change in Blood Flow (ml/min-1/g-1) 
     CON (n=12-18)         MCT (n=11-14) 
 
p-value 
Gastrocnemius 1.62 ± 0.32 0.750 ± 0.20* 0.0230 
Rectus femoris 3.19 ± 0.94 0.723 ± 0.19* 0.0104 
Biceps femoris 0.706 ± 0.20 0.351 ± 0.096 0.0948 
EDL 1 ± 0.396 0.288 ± 0.056 0.0530 
Tibialis anterior 1.65 ± 0.57 0.47 ± 0.074* 0.0363 
Vastus lateralis 1.56 ± 0.51 0.132 ± 0.053* 0.0178 
Soleus 1.79 ± 0.47 0.454 ± 0.29* 0.0194 
Semitendinosus 0.893 ± 0.21 0.498 ± 0.13 0.1115 
Diaphragm 0.40 ± 0.164 0.175 ± 0.25 0.5061 
Table 4.4: Change in blood flow from rest to exercise 
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Figure 4.5: Change in blood flow from rest to exercise 
 
Complied Blood Flow 
In addition to presenting data for individual skeletal muscle groups, it is helpful to 
look at compiled skeletal muscle blood flow values as well. Compiled flow was 
calculated as an average of blood flow across all skeletal muscle groups for each animal, 
with one value representing a ‘global skeletal muscle blood flow’ (Ferguson et al., 2016). 
This was done for both the resting and exercise condition for each animal.  Using the 
compiled skeletal muscle blood flow value, blood flow at rest was not different at rest 
between MCT and CON rats (0.33 ± 0.037 vs. 0.42 ± 0.051 mL/min-1/g-1, p=0.18) but 
was significantly reduced during exercise in MCT (0.86 ± 0.13 vs. 2.28 ± 0.45, p=0.004, 
Figure 4.6). When expressed as percent change from rest to exercise,  compiled skeletal 
muscle blood flow tended to be reduced in MCT rats vs CON (165.1 ± 45.39 vs. 590.9 ± 
232.2, p=0.07). When expressed as absolute change from rest to exercise (Figure 4.7), 
compiled skeletal muscle blood flow was significantly attenuated in MCT compared to 
CON (0.498 ± 0.12 vs. 1.67 ± 0.44, p=0.008). 
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Figure 4.6: Compiled blood flow from rest to exercise with % change 
 
 
 
 
 
Figure 4.7: Compiled blood flow from rest to exercise with absolute change 
 
 
 
 
 
 
 
 
 
 
 
 
* 
p=0.07 
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Resting and Exercise Metabolism 
 
Whole blood lactate was significantly increased both at rest (5.424mmol/L ± 1.03 
vs. 2.04mmol/L ± 0.15, p=0.007) and during exercise (11.47mmol/L ± 0.89 vs. 
4.92mmol/L ± 0.55, p=<0.001) for MCT vs. CON (Figure 4.8). Change in lactate from 
rest to exercise (Figure 4.9) was significantly increased in MCT compared to CON 
(6.59mmol/L ± 0.77, n=21 vs. 2.88mmol/L ± 0.54, n=16, p=<0.001). 
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Figure 4.8: Blood lactate at rest and exercise 
 
 
 
 
 
Figure 4.9: Change in blood lactate from rest to exercise 
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Associations Between Blood Flow and Other Measures 
 
Compiled skeletal muscle blood flow, as described previously, was used to 
represent global limb muscle blood flow in MCT and CON rats, and used in a correlation 
analysis to explore the relationships between blood flow and other variables of interest, 
including exercising metabolism and classic PAH disease measures. 
 
 
Blood Flow and Metabolism 
 
Blood flow was not related to whole blood lactate at rest (r=-0.2006, p=.31) but 
was significantly associated during exercise for all rats (r=-0.5879, p=0.001), and this 
relationship was strengthened in a sub-group analysis of MCT rats only (r=-0.672, 
p=0.003, Figure 4.10) 
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Figure 4.10: Blood flow and exercising lactate 
 
Blood Flow and Disease Measures 
Compiled blood flow at rest was not related to disease measures and cardiac 
function in either MCT or CON. Importantly, compiled blood flow during exercise was 
significantly related to many disease indicators (Figure 4.11) including Fulton Index (r=-
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0.42, p=0.03), RV weight (r=-0.47, p=0.01), resting cardiac output (r=0.47, p=0.02) and 
cardiac index (r=0.46, p=0.035).  There were no significant associations detected for 
compiled blood flow and stroke volume and RV thickness as measured by 
echocardiography, however in each instance a tendency toward significance was reported 
(p=0.08). In a separate analysis considering only MCT rats, there were no significant 
associations between compiled exercising skeletal muscle blood flow and the 
aforementioned disease measures.  
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Figure 4.11: Exercising blood flow and disease measures 
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Resting and Exercise Skeletal Muscle Blood Flow Examined for Just PL Rats 
The analysis above focused on comparing blood flow between MCT and CON 
and utilized all rats regardless of BRJ or PL dosing in the terminal experiment. While it 
will be shown that BRJ had limited effect on blood flow (Aim 2), for completeness, the 
following analysis will look at blood flow in only those animals that received PL. As a 
result, rat numbers are reduced from 12-16 to 6-8 per group, likely under powering 
statistical analysis and limiting the ability to detect differences between MCT and CON. 
For example, when examined for resting blood flow, there were no significant differences 
between MCT and CON, other than for diaphragm, which was significantly higher in 
MCT (Table 4.5). When examined during exercise (Table 4.6), blood flow for MCT vs. 
CON was only significantly lower in the EDL (p=0.043), and tended to be less in rectus 
femoris (p=0.089), biceps femoris (p=0.055), tibialis anterior (p=0.07) and 
semitendinosus (p=0.092) for MCT vs. CON.  
 
 
Muscle 
Resting Blood Flow (ml/min-1/g-1) 
CON+PL (n=6-8)         PAH+PL (n=6-8) 
 
p-value 
Gastrocnemius 0.29 ± 0.06 0.25 ± 0.056 0.67 
Rectus Femoris 0.38 ± 0.093 0.39 ± 0.09 0.96 
Biceps Femoris 0.15 ± 0.04 0.084 ± 0.01 0.12 
EDL 0.25 ± 0.068 0.27 ± 0.09 0.87 
Tibialis anterior 0.29 ± 0.06 0.18 ± 0.04 0.13 
Vastus lateralis 0.17 ± 0.03 0.14 ± 0.02 0.55 
Soleus 0.91 ± 0.37 0.88 ± 0.16 0.93 
Semitendinosus 0.37 ± 0.15 0.16 ± 0.02 0.17 
Diaphragm 1.12 ± 0.099 2.11 ± 0.22** 0.002 
Table 4.5: Resting blood flow in PL rats 
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Muscle 
Exercising Blood Flow (ml/min-1/g-1) 
     CON+PL(n=5-8)    PAH+PL (n=7-8) 
 
p-value 
Gastrocnemius 2.83 ± 1.03 0.94 ± 0.31 0.10 
Rectus Femoris 4.28 ± 1.56 1.34 ± 0.41 0.089 
Biceps Femoris 1.12 ± 0.29 0.46 ± 0.13 0.055 
EDL 1.94 ± 0.61 0.44 ± 0.12 0.043 
Tibialis anterior 2.38 ± 0.95 0.64 ± 0.13 0.07 
Vastus lateralis 2.06 ± 0.86 0.51 ± 0.15 0.1 
Soleus 2.80 ± 0.72 1.41 ± 0.48 0.12 
Semitendinosus 1.6 ± 0.52 0.6 ± 0.2 0.092 
Diaphragm 1.58 ± 0.2 2.34 ± 0.48 0.26 
Table 4.6: Exercising blood flow in PL rats 
 
Skeletal Muscle Capillarization 
 To further characterize skeletal muscle in PAH, capillarization was analyzed in a 
type I (soleus) and type II (EDL) muscles. An antibody cocktail of Wheat Germ 
Agglutinin, lectin and DAPI stained muscle cross sections green (cell membrane), red 
(vasculature) and blue (nuclei) respectively. Resulting yellow structures are identified as 
capillaries, and are expressed as capillaries per myocyte in each field (Figure 4.12). Scale 
bars on each image indicate a length of 100um. There were no significant differences in 
capillarization in either EDL (p=0.12) or soleus (p=0.85) muscles between MCT and 
CON rats (Table 4.7) 
 
Muscle CON  
(capillaries per myocyte) 
MCT 
(capillaries per myocyte) 
EDL  0.96 ± 0.03 1.1 ± 0.05 
Soleus 1.42 ± 0.12 1.45 ± 0.06 
Table 4.7: Capillaries per myocyte in EDL and soleus 
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Ca 
 
 
 
 
 
 
 
 
 
Figure 4.12: Capillaries (yellow), myocyte membrane (green), vasculature (red), nuclei 
(blue) in muscle sections 
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Aim 2 
Plasma Nitrate and Nitrite after BRJ and PL Supplementation 
In order to determine the effect of dietary nitrate in improving blood flow during 
exercise, it was important to test the efficacy of a single dose of BRJ in increasing 
bioavailability of nitrate and nitrite in vivo. If NO is to be upregulated via the NO3--NO2--
NO pathway as outlined, an increase in nitrate and nitrite levels after supplementation 
would be an important finding. Plasma samples were analyzed for NO3- and NO2- via 
High Performance Liquid Chromatography (HPLC), and integrated against known 
nitrate/nitrite standards, providing reliable measures of each. The following analysis will 
first consider the effect of BRJ and PL on plasma NO3-/NO2-, before moving to 
measurement in the tissue of interest (skeletal muscle). As results are expressed for 
BRJ/PL across MCT and CON rats, it is also possible to interrogate any potential effect 
of MCT on plasma/muscle levels of nitrate and nitrite post gavage. Figure 4.13 shows 
plasma nitrate and nitrite levels after BRJ and PL supplementation in each group. Plasma 
nitrate was significantly elevated in rats that received BRJ when compared to rats that 
received PL for CON (555.1 ± 56.28umol/L, n=10 vs. 27.62umol/L ± 3.68, n=9, 
p=<0.001) and MCT (756.4 ± 118.3umol/L , n=9 vs. 63.36umol/L ± 22.46, p=<0.001). 
The effect that the BRJ dosing had on elevating plasma nitrate was not different between 
MCT and CON rats (p=.13). Similarly, plasma nitrite was significantly elevated in rats 
that received BRJ when compared to rats that received PL for CON (0.81 ± 0.12umol/L, 
n=11 vs. 0.33 ± 0.039umol/L, n=8) and MCT (0.63 ± 0.079umol/L, n=9 vs. 0.24 ± 
0.045umol/L, n=6), and there was no difference in the plasma nitrite-elevating effect of 
BRJ when compared between CON and MCT groups (p=0.25). 
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Figure 4.13: Plasma nitrate and nitrite after BRJ or PL supplementation 
 
 
Skeletal Muscle Nitrate and Nitrite after BRJ and PL Supplementation 
Soleus 
Previous studies have looked at plasma nitrate and nitrite as a means of 
determining supplementation effectiveness, however, interrogating bioavailability at the 
skeletal muscle level is an essential step, made possible by recent advances in 
measurement of each in muscle tissue. Briefly, frozen muscle tissue was pulverized and 
combined with methanol, 0.5% triton X-100 and oxypurinol before centrifugation. 
Supernatant was then injected in the HPLC machine and NO3-/NO2- measured. An 
increase in muscle nitrate and nitrite after acute BRJ supplementation would allow for a 
tissue-specific interrogation of dose effectiveness, as well as providing new data on 
nitrate/nitrite storage and activity in a type I (soleus) and type II (vastus lateralis) 
muscles. Figure 4.14 shows soleus nitrate and nitrite levels after BRJ or PL 
supplementation in each group. Soleus nitrate was significantly higher in rats that 
received BRJ vs. PL in CON (336.3pmol/mg ± 73.27, n=6 vs. 159pmol/mg ± 27.35, n=6, 
** 
** ** 
** 
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p=0.046) and MCT rats (282.8pmol/mg ± 31.95, n=5 vs. 121pmol/mg ± 24.07, n=4, 
p=0.006). Soleus nitrite was not different across groups (CON, p=0.88 and MCT, p=.13). 
There was also no difference in the effect of BRJ on soleus nitrate (p=0.55) or nitrite 
(p=0.39) levels between CON and MCT. 
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Figure 4.14: Soleus nitrate and nitrite after BRJ or PL supplementation 
 
Vastus Lateralis 
Figure 4.15 shows vastus lateralis nitrate and nitrite levels after BRJ or PL 
supplementation in each group. Vastus lateralis nitrate was significantly higher in rats 
that received BRJ vs. PL in CON (165.7pmol/mg ± 24.19, n=9 vs. 159pmol/mg ± 79.08 ± 
15.72, n=10, p=0.07) and MCT rats (173.6pmol/mg ± 39.45, n=7 vs. 79.38pmol/mg ± 
13.57, n=9 p=0.025). However, similar to what was observed for the soleus, nitrite was 
not different across groups (CON, p=0.26 and MCT, p=.66), and there was also no 
difference in the effect of BRJ on vastus lateralis nitrate (p=0.86) or nitrite (p=0.51) 
levels between CON and MCT.  
**  * 
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Figure 4.15: Vastus lateralis nitrate and nitrite after BRJ or PL supplementation 
 
 
Dietary Nitrate Supplementation and Blood Flow 
 
In CON rats at rest, there were no significant differences in muscle blood flow for 
rats that received BRJ vs. PL (Table 4.8), however, blood flow tended to be greater in the 
gastrocnemius (p=0.09) and vastus lateralis (p=0.052) for rats that received BRJ vs. PL. 
There were no significant differences in exercising blood flow in CON rats, when rats 
that received PL are compared to rats that received BRJ (Table 4.9).  
 
Muscle 
Resting Blood Flow (ml/min/g) 
CON+PL (n=6-8)    CON+BRJ (n=6-8) 
 
p-value 
Gastrocnemius 0.29 ± 0.06 0.57 ± 0.15 0.09 
Rectus femoris 0.38 ± 0.09 0.69 ± 0.27 0.27 
Biceps femoris 0.15 ± 0.04 0.27 ± 0.07 0.16 
EDL 0.25 ± 0.07 0.46 ± 0.18 0.32 
Tibialis anterior 0.29 ± 0.06 0.42 ± 0.08 0.26 
Vastus lateralis 0.17 ± 0.03 0.35 ± 0.08 0.052 
Soleus 0.91 ± 0.37 0.89 ± 0.18 0.95 
Semitendinosus 0.37 ± 0.15 0.35 ± 0.06 0.87 
Diaphragm 1.11 ± 0.09 1.11 ± 0.09 0.93 
Table 4.8: Resting blood flow in CON rats with either BRJ or PL supplementation 
 
 
 *  * 
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Muscle 
Exercising Blood Flow (ml/min/g) 
  CON+PL (n=5-8)    CON+BRJ (n=7-8) 
 
p-value 
Gastrocnemius 2.83 ± 1.03 2.26 ± 0.44 0.64 
Rectus femoris 4.28 ± 1.56 3.75 ± 1.15 0.79 
Biceps femoris 1.12 ± 0.29 0.89 ± 0.17 0.50 
EDL 1.94 ± 0.61 1.05 ± 0.40 0.24 
Tibialis anterior 2.38 ± 0.95 1.87 ± 0.66 0.67 
Vastus lateralis 2.06 ± 0.86 2.36 ± 1.09 0.83 
Soleus 2.8 ± 0.72 2.85 ± 0.52 0.95 
Semitendinosus 1.6 ± 0.52 1.31 ± 0.29 0.63 
Diaphragm 1.58 ± 0.2 1.61 ± 0.33 0.96 
Table 4.9: Exercising blood flow in CON rats with either BRJ or PL supplementation 
 
In MCT rats at rest (Table 4.10), blood flow in the biceps femoris was 
significantly elevated in rats that received BRJ vs. PL, and tended to be greater in the 
rectus femoris (p=0.09) and semitendinosus (p=0.09). There were no significant 
differences in exercising blood flow in MCT rats that received BRJ vs. PL (Table 4.11). 
 
 
Muscle 
Resting Blood Flow (ml/min/g) 
 MCT+PL (n=6-9)    MCT+BRJ (n=6-9) 
 
p-value 
Gastrocnemius 0.25 ± 0.06 0.20 ± 0.03 0.43 
Rectus femoris 0.39 ± 0.09 0.23 ± 0.03 0.09 
Biceps femoris 0.08 ± 0.01 0.18 ± 0.03* 0.03 
EDL 0.27 ± 0.09 0.15 ± 0.02 0.19 
Tibialis anterior 0.18 ± 0.04 0.18 ± 0.03 0.93 
Vastus lateralis 0.14 ± 0.02 0.22 ± 0.05 0.26 
Soleus 0.88 ± 0.16 0.89 ± 0.15 0.95 
Semitendinosus 0.16 ± 0.02 0.34 ± 0.09 0.09 
Diaphragm 2.1 ± 0.22 2.07 ± 0.38 0.93 
Table 4.10: Resting blood flow in MCT rats with either BRJ or PL supplementation 
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Muscle 
Exercising Blood Flow (ml/min/g) 
    MCT+PL (n=7-8) MCT+BRJ (n=8-9) 
 
p-value 
Gastrocnemius 0.94 ± 0.31 1.25 ± 0.3 0.48 
Rectus femoris 1.34 ± 0.41 1.37 ± 0.36 0.96 
Biceps femoris 0.46 ± 0.13 0.57 ± 0.17 0.62 
EDL 0.44 ± 0.12 0.52 ± 0.08 0.57 
Tibialis anterior 0.64 ± 0.13 0.77 ± 0.08 0.41 
Vastus lateralis 0.51 ± 0.15 0.35 ± 0.08 0.36 
Soleus 1.41 ± 0.48 1.41 ± 0.31 0.99 
Semitendinosus 0.6 ± 0.2 0.9 ± 0.15 0.23 
Diaphragm 2.34 ± 0.48 2.2 ± 0.25 0.74 
Table 4.11: Exercising blood flow in MCT rats with either BRJ or PL supplementation 
 
Dietary Nitrate Supplementation and Metabolism 
There were no significant differences in blood lactate concentration at rest or 
during exercise between rats that received BRJ vs. PL in either MCT or CON rats (Figure 
4.16).  
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Figure 4.16: Blood lactate at rest and exercise after BRJ or PL supplementation 
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Plasma NO3-/NO2- and Blood Flow/Metabolism 
While no significant correlations existed between plasma nitrate/nitrite and 
compiled muscle blood flow at either rest or exercise under each dosing strategy, BRJ 
supplemented rats demonstrated a significant negative association between plasma nitrite 
(NO2-) and exercising plasma lactate (r=-0.5694, p=0.017, Figure 4.17) and a tendency 
toward significance for resting lactate (r=-0.4179, p=0.095).  
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Figure 4.17: Plasma nitrite and exercising lactate after BRJ supplementation 
 
Skeletal Muscle NO3-/NO2- and Blood Flow/Metabolism 
Neither soleus nitrate nor nitrite were significantly associated with compiled 
resting or exercising skeletal muscle blood flow. Additionally, soleus nitrate and nitrite 
were not significantly related to blood flow specific to the soleus muscle at rest or 
exercise in either the BRJ or PL condition. A significant association between soleus NO3- 
and lactate at exercise was present in animals supplemented with PL in the terminal 
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experiment (r=-.73, p=0.04), however, no further associations were reported for the 
soleus muscle and blood flow or metabolism. In the vastus lateralis, there were no 
significant associations between muscle nitrite (NO2-) and blood flow at rest or exercise 
(including specific to the vastus lateralis) or blood lactate in either BRJ or PL conditions. 
Similarly, vastus latetralis nitrate (NO3) was not associated with blood flow or 
metabolism measures at rest or during exercise after either BRJ or PL supplementation.  
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Aim 3 
In order to test the hypothesis that BRJ supplementation can improve functional 
exercise performance, pre and post MCT testing was carried out for maximal aerobic 
capacity, voluntary wheel running distance and grip strength under both BRJ and PL 
supplementation. Each exercise test was carried out in a counterbalanced fashion, with 
each rat (MCT and CON) performing under repeated trials of BRJ and PL, separated by 
24hrs. Therefore, the following results are based on repeated measures statistical testing, 
allowing for a within-rat comparison of BRJ effectiveness in altering functional 
performance. Data for the BRJ condition will be graphically presented as striped bars.   
 
Functional Testing – VO2max 
Repeated treadmill testing of VO2max was carried out pre and post injection 
using a graded exercise protocol to exhaustion. Running took place between 2-3 hours 
post supplementation, ensuring optimal timing in accordance with measured increases in 
plasma nitrate/nitrite (Appendix A). Post MCT induction, VO2max was significantly 
reduced compared to CON in both PL (3190 ± 245.5 ml/kg/hr, n=14 vs. 4308 ml/kg/hr ± 
110.5, n=18, p=<0.001) and BRJ (3074 ml/kg/hr ± 302.5, n=16 vs. 4162 ml/kg/hr ± 
192.2, n=16, p=0.005) conditions (Figure 4.18).  In both pre and post MCT/vehicle 
testing, repeated measures VO2max was not significantly improved by BRJ 
supplementation in comparison to PL for either MCT or CON rats. In final testing, 
VO2max was decreased an average of 193.7 ml/kg/hr by BRJ (-5.1%) for CON rats 
(n=16), and increased 139.4ml/kg/hr (3.9%) in MCT (n=11) (Figure 4.19).  
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Figure 4.18: Final VO2max under BRJ and PL conditions 
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Figure 4.19: VO2max under BRJ and PL conditions in pre-injection and final 
testing 
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Time to exhaustion during VO2max testing was significantly different between 
MCT and CON in final testing under both PL (n=13-18, 10.68 min ± 1.857 vs. 18.08 min 
± 1.554, p=0.004) and BRJ (n=13-14, 12.07 min ± 2.052 vs. 20.27 min ± 1.341, p=0.003) 
conditions (Figure 4.20). In both pre-injection and final testing, time to exhaustion was 
not improved by BRJ supplementation in comparison to PL for either MCT or CON rats 
(Figure 4.21). In final testing, time to exhaustion was decreased an average of 0.58mins 
by BRJ for CON rats (n=13), and increased 1.9mins in MCT (n=11). 
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Figure 4.20: Final time to exhaustion under BRJ and PL conditions 
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Figure 4.21: Time to exhaustion under BRJ and PL conditions in pre-injection and final 
testing 
** ** 
p=0.61 
p=0.12 
  93    
RER at 50% VO2max 
 
  Respiratory exchange ratio (RER) considers the relative amounts of oxygen 
consumed and carbon dioxide exhaled, and can be used as a metabolic measure and/or 
indicator of substrate use during exercise. Measuring RER at 50% VO2max (the same 
intensity of terminal blood flow experiments) may give an indication as to altered 
metabolism at the same relative exercise intensity under either BRJ or PL conditions in a 
within-animal design. In final testing, RER at moderate exercise intensity (50% VO2max) 
was not significantly different between the BRJ and PL conditions in either CON (n=13, 
p=0.41) or MCT (n=7, p=0.17) (Figure 4.22). 
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Figure 4.22: RER at 50% VO2max  
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Functional Testing – Grip Strength 
Repeated grip strength tests were carried out 24hr apart in both pre-injection and 
final testing using the specialized rodent dynamometer in a counterbalanced design. Grip 
tests were completed 2-3hrs post gavage to ensure optimal supplement timing, with an 
average of three trials calculated. In final testing, grip strength was not different between 
MCT (n=13-14) and CON (n=17) under PL or BRJ conditions (Figure 4.23).  
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Figure 4.23: Final grip strength under BRJ and PL conditions 
 
 
In both pre-injection and final testing, grip strength was not improved by BRJ 
supplementation in comparison to PL for MCT, but tended to be increased for CON rats 
(p=0.07, Figure 4.24). In final testing, grip strength was increased an average of 128.6g 
(14.19%) by BRJ for CON rats (n=15), and decreased 110.2g (-4.6%) in MCT (n=12). 
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Figure 4.24: Grip strength under BRJ and PL conditions in pre-injection and final testing 
 
 
Functional Testing – Voluntary Wheel Running 
            Voluntary 12-hour wheel running was carried out pre and post injection under 
BRJ and PL conditions for each rat in a counterbalanced fashion. As the vast majority of 
running takes place in the dark hours, supplementation of BRJ and PL was timed 2-3 
hours prior to the initiation of darkness, ensuring consistency in dosing and subsequent 
exercise measurement. In pre-injection testing, there were no differences in running 
distance between groups under either the BRJ (1230 m ± 300.1, n=16 vs. 1245 m ± 
144.4, n=15, p=0.97) or PL conditions (989 m ± 318.4, n=16 vs. 1477 m ± 180.9, n=15, 
p=0.20) In final testing, voluntary wheel running distance tended to be lower in MCT vs. 
CON (Figure 4.25), in both the PL (p=0.08, n=12-16) and BRJ condition (p=0.12, n=11-
16). In both pre-injection and final testing, voluntary wheel running distance was not 
p=0.07 p=0.29 
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improved by BRJ supplementation in comparison to PL for either MCT or CON rats 
(Figure 4.26), with BRJ supplementation decreased running distance 172.5m for CON 
(n=15) and 145.3m for MCT (n=9).  
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Figure 4.25: Final voluntary running distance under BRJ and PL conditions 
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Figure 4.26: Voluntary running distance under BRJ and PL conditions in pre-injection 
and final testing. 
p=0.08 p=0.12 
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In final testing, wheel running speed was not significantly different between MCT 
and CON in the PL condition (19.27 m/min ± 1.504, n=16 vs. 19 m/min ± 1.996, n=12, 
p=0.91) however, it tended to be higher in MCT after BRJ supplementation compared to 
CON under the same condition (21.24 m/min ± 0.8208, n=16 vs. 18.88 m/min ± 0.8087, 
n=11, p=0.06). In both pre-injection and final and post MCT/vehicle testing, repeated 
measures voluntary wheel running speed was not improved by BRJ supplementation in 
comparison to PL for either MCT or CON rats (Figure 4.27).  
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Figure 4.27: Voluntary running speed under BRJ and PL conditions in pre-injection and 
final testing 
 
 
 
 
 
p=0.06 
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Chapter Five: Discussion 
Summary 
 This study sought to characterize skeletal muscle blood flow at rest and during 
exercise in an experimental model of PH, with a specific emphasis on reduced blood flow 
as a contributor to exercise intolerance in the disease. Additionally, the use of dietary 
nitrate as a potential mechanism to augment blood flow and improve functional capacity 
was investigated. This analysis has added to the body of knowledge in PH, most notably 
by identifying a pathological hemodynamic response to exercise in a reliable animal 
model of the condition. While it is clear further mechanistic insight into this problem is 
warranted, a novel target to potentially improve exercise capacity in PAH has been 
identified. Although dietary nitrate was not an effective mediator of blood flow and 
exercise performance (in either MCT or CON rats), mechanistic analysis has provided a 
potentially novel explanation for its lack of efficacy under these conditions. The 
preliminary work of measuring muscle nitrate and nitrite should be complemented by 
further study into the handling, transport and activity of these ions in tissues of interest. 
Expanding this investigation to their downstream target is a logical approach to further 
understand the conditions under which dietary nitrate may produce an ergogenic effect at 
the skeletal muscle level in health and disease.  
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PH Phenotype 
 A single subcutaneous injection of MCT, as used in this study, has been 
demonstrated to produce a progressive pulmonary hypertensive phenotype (Stenmark et 
al., 2009). While the exact mechanisms by which this occurs is still under investigation 
(Gomez-Arroyo et al., 2012), it is well known that increasing doses of MCT reliably 
leads to more severe affliction. Importantly, the dose can be administered to ‘mimic’ 
either compensatory hypertrophy, or increased to illicit characteristics of RV failure 
(Handoko et al., 2009). This is important, as it has previously been described that a 
transition from functional to detrimental RV hypertrophy is critical in determining 
survival in the disease. Several studies have specifically tested an increasing MCT dose 
and the subsequent genetic, morphological and functional changes in the RV (Buermans 
et al., 2005; Handoko et al., 2009; Hessel et al., 2006), with one study specifically 
measuring cardiac parameters at bi-weekly intervals after MCT injection (Sutendra et al., 
2013). Here, RV failure was shown via a loss of pump function, manifested by a 
significant reduction in cardiac output at 6 weeks post 60mg/kg MCT administration. Our 
results would suggest a similar phenotype, with significant reductions in stroke volume 
(~18%), cardiac output (~23%) and cardiac index (~14%) in MCT vs. CON animals all 
demonstrated. The decline in RV function presented herein mirrors that of Hessel et al. 
(2006), who reported a ~26% reduction in cardiac output 4 weeks after an 80mg/kg MCT 
dose, further supporting a severe phenotype and a progression toward heart failure in our 
model.  
 MCT rats presented with significant RV morphological changes. Direct measures 
(RV weight and Fulton Index) indicated a significant increase in RV hypertrophy in MCT 
  100    
rats, supporting data from similar studies using a higher-dose strategy as employed here 
(Hessel et al., 2006; J. E. Jones et al., 2002; Schermuly et al., 2005; Schermuly et al., 
2004). Additionally, echocardiographic measures demonstrated a ~28% increase in RV 
size in MCT rats compared to CON. These findings supports previous data that 
established a progressive increase in RV size post MCT injection, with a difference 
between treated and control rats apparent approximately 4 weeks post disease induction 
(Hessel et al., 2006; J. E. Jones et al., 2002; Kim, Kim, Chan, Kim, & Sohn, 2018). As 
noted at the outset, a direct measurement of RV pressures are required to diagnose PAH 
in clinical populations, with an increased pulmonary mean arterial pressure of >25mmHg 
considered the criterion standard for disease presence (Galie et al., 2016). An increase in 
RVSP has been reported in the MCT model (Gomez-Arroyo et al., 2012), and this data is 
supported here. A mean RVSP of 52mmHg in MCT rats is similar to that recorded by 
other investigators (Handoko et al., 2009; Sutendra et al., 2013), and represented a 116% 
increase over CON. However, pressures of >75mmHg have been reported in rats after 
60mg/kg MCT dose (Benoist, Stones, Drinkhill, Bernus, & White, 2011; Klein et al., 
2008), indicating that greater doses may illicit adaptations in the RV beyond those 
described here.  
 Further to the aforementioned RV maladaptations of the MCT model, an 
additional indication of the progression toward heart failure are the body weight 
alterations noted after injection. Here, we describe no significant differences at injection, 
with a progression toward significantly lower body weights in the MCT group at 4 
weeks. This supports the work of Hessel et al. (2006) who noted a significant retardation 
of weight gain in high dose MCT rats compared to controls, which, importantly, may 
  101    
mimic the cachexic effects of heart failure in patient populations. Finally, a reduction in 
exercise capacity was apparent in MCT rats. Aerobic capacity (VO2max) was 
significantly lower (p=<0.05) in MCT rats compared to controls, with voluntary wheel-
running distance also tending to be lower (p=0.08), representing a 26% and 45% decline 
respectively. This reduction in functional capacity supports previous work done in 
pulmonary hypertensive animal models (M. B. Brown et al., 2015; M. B. Brown et al., 
2017; Frump et al., 2015; Lahm et al., 2016), and in patient populations (Badagliacca et 
al., 2017; Breda et al., 2014; Malenfant, Potus, Mainguy, et al., 2015; Potus et al., 2014; 
Provencher et al., 2006; Spruijt et al., 2015; Sun et al., 2001; Tolle et al., 2008), who have 
consistently demonstrated lower walking distances and aerobic capacity when compared 
to healthy controls. Taken together, the clear decrements in cardiac function, 
morphological adaptations in the RV, blunted weight gain and decreased exercise 
performance would suggest a robust pulmonary hypertensive animal model, with a severe 
phenotype characteristic of progression toward heart failure.  
 
Aim 1 
 Hypothesis 1.1 – Skeletal muscle blood flow will be significantly reduced at rest 
and during exercise in a PAH rat model, when compared to healthy controls.  
 
 The most significant finding in this study is the reduction in skeletal muscle blood 
flow at rest, and more prominently during exercise, in a pulmonary hypertensive animal 
model. The microsphere method of blood flow analysis has also allowed us to confirm 
the persistence of reduced flow while accounting for blunted cardiac output in MCT rats. 
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To the author’s knowledge, this is the first study to demonstrate such a deficiency, and 
adds to the understanding of skeletal muscle dysfunction and exercise intolerance in 
PAH. Regardless of supplementation, significant reductions in flow were demonstrated at 
rest in 2 of the 8 hind limb muscles analyzed (tibialis anterior and gastrocnemius). 
Crucially, during moderate intensity exercise, blood flow was significantly lower in each 
of the skeletal muscles sampled. Additionally, it was shown that the increase in muscle 
blood flow from rest to exercise was attenuated in 5 of the 8 skeletal muscles sampled in 
MCT rats (gastrocnemius, tibialis anterior, rectus femoris, vastus lateralis, soleus), 
providing further mechanistic insight into the blunted exercise response in PAH. In a sub-
group analysis of rats supplemented with PL, exercising blood flow was significantly 
reduced in the EDL (p=0.043), with a tendency for reduced flow in the rectus femoris, 
biceps femoris, tiblialis anterior, and semitendinosus (p=0.05 to 0.92). 
 Vescovo et al. (1998) highlighted a reduction in skeletal muscle blood flow at rest 
in a heart failure rat model, however, this discrepancy was demonstrated in the soleus 
muscle, contrary to our findings. Interestingly, we have shown a tendency for reduced 
flow at rest in the EDL (p=0.054), but no significant difference was seen in the Vescovo 
study. While this is the first investigation to directly measure exercising skeletal muscle 
blood flow in a pulmonary hypertensive animal model, our findings can be linked to 
previous work in this area. Others have shown that circulatory maladaptations at the 
skeletal muscle level contribute to a reduced exercise performance in PAH (Dimopoulos 
et al., 2013; Malenfant, Potus, Mainguy, et al., 2015; Potus et al., 2014; Tolle et al., 
2008). Microcirculatory loss, reduced oxygen saturation/extraction and slower hyperemia 
responses have all been suggested as peripheral mechanisms restricting exercise tolerance 
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in PAH, and a directly-measured blood flow reduction may now be considered as a 
corollary limitation. It is well established that at exercise, oxygen delivery via increase 
blood flow is increased to meet the rising metabolic demands of skeletal muscle (Poole, 
Hirai, Copp, & Musch, 2012; Sarelius & Pohl, 2010). It stands to reason that a reduction 
in blood flow to working muscle may predicate downstream effects including reduced 
oxygen supply (Malenfant, Potus, Mainguy, et al., 2015) and extraction (Tolle et al., 
2008). Interestingly, while central limitations are apparent during exercise in PAH, it has 
been argued that peripheral abnormalities such as those highlighted may be greater 
contributors to the early onset of fatigue present in the disease, primarily because exercise 
training has improved functional capacity without significant changes in central 
hemodynamics (L. Chan et al., 2013; Fox et al., 2011; Mereles et al., 2006).  
 Blood flow limitations during exercise have been characterized to a greater extent 
in left heart failure, and the data tends to support the findings in this study. In early work, 
Drexler, Faude, Hoing, and Just (1987) demonstrated a significant reduction in blood 
flow to the red portion of the gastrocnemius during maximal exercise in an infarct model 
of left heart failure.  These findings were supported by later work that showed greater 
reductions in muscle blood flow at rest and during exercise in a similar model, with rats 
more severely afflicted demonstrating the most profound decrements in blood flow to 
exercising muscles (Musch & Terrell, 1992).  Importantly, this was the first study to 
show that a more severe heart failure phenotype predicated a greater reduction in blood 
flow. These early works have since been supported by a plethora of studies investigating 
exercises responses in heart failure, comprehensively reviewed by Poole et al. (2012). It 
has been shown that central limitations in heart failure only partially explain a reduction 
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in blood flow to working muscles in LHF. While a reduced cardiac output may decrease 
the speed and magnitude of blood supply to skeletal muscle at the onset of exercise, 
systemic vasoconstriction, vascular stiffness, endothelial dysfunction, inflammatory 
markers and reduced NO bioavailability are all postulated as factors culminating in 
compromised exercising blood flow in the disease (Poole et al., 2012). A further 
exploration of these factors may be crucial in understanding the deficits shown in this 
study, as each of the aforementioned abnormalities have also been identified in PAH 
(Humbert, 2010; Price et al., 2012; Rosenblum, 2010; Toshner et al., 2010; Zuckerbraun 
et al., 2011).  
 One further mechanistic explanation for a reduction in muscle blood flow could 
be a reduction in capillarization in PAH. Potus et al. (2014) described significant 
angiogenic deficiencies in the quadriceps muscles of PAH patients, and were able to 
directly connect this microcirculatory loss to exercise intolerance. A downregulation of 
the angiogneic signaling miR-126 was apparent in PAH muscle, and correlated with a 
reduction in exercise capacity. Interestingly, exercise training had no effect on miR-216 
expression, and as such, it is argued that physical inactivity is not sufficient to explain 
muscle-specific maladaptations that contribute to exercise intolerance in the disease. In 
line with these findings, reduced capillarization was demonstrated in the RV of an MCT 
rat model, secondary to downregulation of the HIF-1 pathway (Sutendra et al., 2013). 
This would indicate a microcirculatory myopathy that extends to both the myocardium 
and peripheral muscle in PAH. While reduced skeletal muscle capillarity could provide 
an explanation for reduced blood flow, we did not see a significant difference in capillary 
numbers between MCT and CON rats. Investigating capillary numbers in the EDL and 
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soleus allowed for potential discrepancies between primarily Type I and Type II muscle 
fibers (Armstrong & Phelps, 1984) , however, in each case MCT did not induce 
rarefaction at the myocyte level. This seems to contrast to the findings of Sutendra et al. 
(2013) who showed reduced capillarity in the RV after MCT injection, however, this 
study measured capillary number at 6 weeks post injection, as opposed to 4 weeks used 
herein. As such, it may be the case that more time is needed post-PH induction to see 
such changes at the skeletal muscle level. Nevertheless, this finding is important as it 
suggests capillary loss may not be an explanation for the observed reduction in blood 
flow, but may also provide insight as to how closely the MCT model might mimic 
skeletal muscle dysfunction in PAH. As such, mechanistic investigations aimed at 
explaining reduced muscle blood flow during exercise in this model should shift toward 
microcirculatory function, rather than morphology. While adequate capillary density may 
exist to meet the increased oxygen demand of working muscle, endothelial dysfunction as 
a consequence of disease may limit vasoreactivity and subsequently reduce blood flow at 
the muscle level. Hence, as noted previously, further investigation is this area is 
warranted.  
 We have demonstrated increased blood lactate accumulation at rest and during 
exercise in a PH rat model. Lactate and hydrogen ions accumulate in the blood as a result 
of several interrelated mechanisms, including a reliance on anaerobic glycolysis, 
conversion of pyruvate to lactate (primarily in Type II muscle fibers), and reduced 
systemic clearance via lactate oxidation.  It is well established that lactate rises with 
increasing exercise intensity, and contributes to the onset of fatigue (McArdle, Katch, & 
Katch, 2015). Previous work in PAH has shown an early accumulation of lactate relative 
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to exercise intensity (Neder et al., 2015), indicating an ineffective switch from aerobic to 
anaerobic means of ATP production. Several mechanisms may explain this phenomenon 
in PAH, including blunted cardiac response to exercise (Holverda et al., 2006; Manders, 
Rain, et al., 2015; Sun et al., 2001; Waxman, 2012) and muscle adaptations that 
compromise oxidative metabolism (Batt et al., 2014; M. B. Brown et al., 2015; de Man et 
al., 2011; Mainguy et al., 2010b; Malenfant, Potus, Fournier, et al., 2015). We have 
added to this understanding by identifying reduced skeletal muscle blood flow as a 
contributor to increased lactate accumulation during exercise. It stands to reason that an 
increased oxygen demand that cannot be met by increased flow would result in an 
overreliance on anaerobic metabolism, and to the authors knowledge, this is the first 
evidence to directly support this phenomenon in a PH model. Indeed, the significant 
inverse relationship between blood flow and lactate accumulation was strengthened in the 
MCT rats specifically, indicating the importance of adequate blood flow in combating 
metabolic disturbance in the disease. 
 Skeletal muscle blood flow was significantly correlated with disease measures, 
including RV hypertrophy and cardiac output. It should be noted while exercising blood 
flow was associated with cardiac output measured at rest, it may the case that an exercise 
stimulus is required to elucidate the connection between central and peripheral 
dysfunction in this model. Prior evidence has shown that exercise stress (such as that 
carried out in an incremental exercise test) may be required to identify physiological 
abnormalities that are central to disease progression, and may indeed have an important 
diagnostic role in the clinical setting (Farina et al., 2018) Indeed, the presence of 
increased RV pressures during exercise have been suggested as a precursor to resting PH 
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(Medarov, Jogani, Sun, & Judson, 2017), however, the variable nature of responses to 
exercise in healthy individuals has made defining an ‘exercise pulmonary hypertension’ 
an ongoing challenge (Provencher, Chemla, & Herve, 2011)  However, it is clear the 
integrated nature of the exercise response can shed light on a host of clinically relevant 
factors, including the metabolic, ventilatory and cardiovascular abnormalities present in 
the disease (Neder et al., 2015), and ultimately determine the severity of disease and 
patient prognosis (Paolillo et al., 2012). The findings herein support this idea, with blood 
flow specifically measured at moderate intensity exercise having a stronger predictive 
power of disease status than that measured at rest.  
 A novel finding in this study is the elevated blood flow to the diaphragm in MCT 
rats at rest, and the tendency for increased flow during exercise (p=0.07), opposing the 
hemodynamic pattern seen in skeletal muscles. There is significant evidence pointing to 
respiratory muscle dysfunction in PAH, including increased proteolytic activity leading 
to diaphragm atrophy (de Man et al., 2011), sarcomeric abnormalities culminating in 
reduced force production in humans (Manders et al., 2012) and atrophy-driven power 
reductions in an MCT rat model (Ahn et al., 2013). These maladaptations have important 
clinical repercussions, as respiratory muscle weakness can exacerbate the feeling of 
breathlessness and fatigue often seen in patient populations (Ahn et al., 2013), while also 
providing some rationale for the compromised ventilatory response to exercise previously 
identified (Sun et al., 2001). In chronic left heart failure, respiratory muscle dysfunction 
has been linked to an increased cost of breathing (Cross, Sabapathy, Beck, Morris, & 
Johnson, 2012; Olson et al., 2010). That is, energy demands of the respiratory muscles 
are heightened at the same level of external work, leading to increased shunting of 
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cardiac output away from skeletal muscle to sustain ventilatory function (de Man et al., 
2011). Hyperventilation has been demonstrated in PAH patients at rest (Naeije, 2005), 
and although this is the first study to highlight an increase in blood flow to the diaphragm 
in a PAH model, it supports the idea of increased oxygen demand and subsequent 
redirection of cardiac output to the respiratory muscles in the disease. Furthermore, while 
not statistically significant, there was a tendency for diaphragmatic flow to be increased 
during exercise in MCT rats, and this supports previous work in left heart failure (Miller, 
Smith, Hemauer, & Dempsey, 2007; Olson et al., 2010). Indeed, it is argued this 
abnormal hemodynamic response may contribute to the decreased exercise tolerance seen 
in that condition (Smith et al., 2018). It seems logical to ‘connect the dots’ and propose 
this as a potential mechanism explaining reduced blood flow to skeletal muscles as 
reported here. During exercise, blood flow is redistributed to those tissues with an 
increased metabolic demand (McArdle et al., 2015), however, the elevated oxygen 
requirements of respiratory muscles, as proposed in PAH, may limit the cardiac output 
available for locomotor muscles, explaining at least in part the reduced skeletal muscle 
blood flow reported here.  
 
Aim 2 
Hypothesis 2.1 – Animals supplemented with BRJ will demonstrate increased 
blood flow in comparison to those supplemented with placebo.  
Hypothesis 2.2 - Animals supplemented with BRJ will demonstrate reduced 
reliance on anaerobic metabolism via lower blood lactate accumulation at rest and during 
exercise. 
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Given the importance of muscle blood flow as a mediator of exercise 
performance, and its reported reduction in a PAH animal model (Aim 1), the study of 
therapeutic interventions that have been demonstrated to increase blood flow during 
exercise is warranted. To do so, an understanding of the mechanisms by which blood 
flow is controlled at the onset of exercise is critical. An expansive review by Sarelius and 
Pohl (2010) identified mediators intrinsic and extrinsic to muscle tissue that are central to 
the redistribution of blood flow during exercise, with specific emphasis on the 
importance of signaling pathways implicated in vasodilation. The review highlights the 
complexity of the vasodilatory response to exercise, identifying metabolic markers such 
as increased lactate/adenosine, mechanical shear stress, acetylcholine, and endothelium-
derived factors such as NO and prostacyclin as having a synergistic effect of rapidly 
increasing flow to working muscle. Indeed, NO has been comprehensively studied, and is 
well characterized as an endothelium-derived vasorelaxing agent and powerful mediator 
of blood flow (Palmer, Ferrige, & Moncada, 1987). NO is made bioavailable as the 
substrate L-arginine is acted on by a group of nitric oxide synthases, ultimately 
upregulating the second messenger cGMP (Moncada & Higgs, 1993). There is evidence 
this pathway is compromised in PAH (Zuckerbraun et al., 2011) and as such, drug 
interventions have focused heavily on its manipulation as a treatment option in the 
disease. Early evidence that NO plays a significant role in muscle blood flow in the rat 
(T. Hirai, Visneski, Kearns, Zelis, & Musch, 1994) has led to more recent work 
demonstrating that increasing NO bioavailability via dietary nitrate intervention can 
improve skeletal muscle blood flow in healthy rats (Ferguson et al., 2014) and chronic 
heart failure models (Ferguson et al., 2016). The use of dietary nitrate is somewhat 
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unique in that it has been shown to increase NO in an oxygen-independent manner, 
outside the traditional L-arginine pathway that is compromised in PAH (Khatri et al., 
2017). Taken together, this would point to a promising therapeutic approach to improve 
muscle blood flow and combat the apparent hemodynamic abnormalities identified in 
Aim 1 of this study. The mechanisms by which dietary nitrate may have a therapeutic 
effect, specifically at the skeletal muscle level, are still under investigation, however, 
supplementation has been shown to increase plasma nitrate and nitrite (Lundberg et al., 
2009), which can theoretically increase NO bioavailability via enzymatic reduction of 
nitrite in vivo. Interestingly, dietary nitrate has been shown to mediate PH progression in 
animal models via altered NO signaling and a reduction of pathologic vascular 
remodeling (Alef et al., 2011; Baliga et al., 2012), however, this is the first study to test 
its efficacy in manipulating blood flow in the disease. 
In this study, an acute dietary nitrate dosing strategy was employed. This is a 
novel approach in rodent models, likely driven by difficulty in administering known 
quantities of a dietary supplement to the intact animal. The potential advantages of the 
acute dose are two-fold; it has previously been shown that a single dose of dietary nitrate 
can increase NO bioavailability and improve exercise performance (Coggan, Leibowitz, 
Kadkhodayan, et al., 2015; Coggan, Leibowitz, Spearie, et al., 2015; Coggan & Peterson, 
2018; Kenjale et al., 2011; Lansley et al., 2011; Murphy, Eliot, Heuertz, & Weiss, 2012; 
Rimer et al., 2016), and from a translational perspective, the simplicity of a one-off, pre-
exercise drink that can potentially increase blood flow would likely be an attractive 
option for patients interested in increasing their exercise tolerance.  
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Contrary to the findings of Ferguson et al. (2016) in the left heart failure rat 
model, we did not see a significant effect of BRJ in augmenting muscle blood flow, 
particularly during exercise. In MCT rats supplemented with BRJ, blood flow to the 
rectus femoris was significantly elevated at rest compared to those given placebo 
(p=0.03), with a tendency for improvement in the rectus femoris and semitendinosus 
muscles (p=0.09), however, no differences were seen during exercise. A similar effect 
was seen in CON rats, with BRJ supplementation tending to increase blood flow to the 
gastrocnemius (p-0.09) and vastus lateralis (p=0.052) at rest, with no apparent 
improvements during running. In the aforementioned left heart failure study, blood flow 
was increased in nine different muscle sections of the ankle extensors, knee extensors and 
knee flexors during exercise after dietary nitrate intervention, with no differences 
reported at rest (Ferguson et al., 2016). Similarly, Casey et al. (2015) showed that in older 
healthy individuals, an acute dose of dietary nitrate increased vasodilation and blood flow 
during subsequent forearm exercise, again seeming to contradict the findings in this 
study.  
In exploring the factors that may have resulted in limited efficacy of BRJ in 
augmenting exercising blood flow, it would be tempting to point to the acute 
administration of nitrate in comparison to the chronic dosing strategy used by Ferguson et 
al. (2016). However, we have shown that a single dose of BRJ significantly increases 
plasma nitrate and nitrite in a similar fashion reported in that study, and in others that 
employed a longer term dietary nitrate intervention (Alef et al., 2011; Bailey et al., 2010; 
Bailey et al., 2009; Baliga et al., 2012; Beijers et al., 2018; Friis et al., 2017; Henrohn et 
al., 2018; Larsen et al., 2011; Smith et al., 2018). As plasma nitrate/nitrite levels are 
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consistently used to demonstrate the effectiveness of BRJ dosing, reporting fold increases 
of ~12-20 and ~2.5 in nitrate and nitrite respectively across MCT and CON groups after 
BRJ gavage goes some way to indicate the efficacy of the acute dosing strategy employed 
here. However, as the rationale for using BRJ to improve blood flow involves increasing 
NO as a precursor to vasodilation and increased flow in skeletal muscle, an important 
next step was to measure nitrate and nitrite in the tissue of interest. Indeed, the 
importance of NO metabolism in skeletal muscle has received increased attention in 
recent years, most notably through the work of Barbora Piknova. This work in rodents 
revealed that skeletal muscle acts as a large nitrate reservoir capable of adding to whole 
body nitrite and NO levels (Piknova et al., 2015), and importantly, that reduction of 
nitrite to NO likely plays a functional role in increasing skeletal muscle blood flow 
during exercise stress (Piknova, Park, Kwan Jeff Lam, & Schechter, 2016). As it is now 
known muscle nitrate and nitrite levels change at the onset of exercise (Piknova et al., 
2016) and that their levels can be altered through dietary intervention (Gilliard et al., 
2018), direct measurement in the tissue of interest may help provide an understanding as 
to the action of the NO pathway we have attempted to manipulate in this study. 
Fortunately, a reliable method using high performance liquid chromatography (HPLC) 
for measuring muscle nitrate/nitrite has recently been developed (Troutman et al., 2018), 
and allows for the precise measurement of each in rodent tissue samples. 
In support of previous work (Piknova et al., 2015), we show that the rat skeletal 
muscle contains higher levels of nitrate and nitrite in comparison to plasma, confirming 
its role as a significant storage site for each in vivo. In both the soleus and vastus lateralis 
muscles, nitrate levels were significantly increased in the BRJ supplemented groups 
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compared to PL, however, there were no differences in muscle nitrite in either tissue. 
This is contrary to the findings in plasma, where both nitrate and nitrite were significantly 
elevated in BRJ rats. Indeed, this finding held true for both MCT and CON rats, with 
MCT seemingly not effecting dietary nitrate handling after gavage. It can be speculated 
that no differences in nitrite, despite elevated nitrate levels in muscle indicates a lack of 
reduction in the NO3--NO2--NO pathway, and therefore, no significant hyperemic effect. 
One would expect an increase in nitrite (and potentially NO), as a consequence of 
reduced nitrate, however, the findings here would call this into question. This would 
seem to coincide with the finding that BRJ was not effective in reducing lactate levels 
during exercise. In both MCT and CON rats, lactate was not significantly different after 
BRJ or PL gavage. While it was demonstrated that plasma nitrite was negatively 
correlated to exercising lactate, this was not the case with nitrate, nor was it related to 
blood flow either in individual muscles or as a compiled blood flow measure.  In relation 
to the findings in Aim 1, if BRJ is unable to increase blood flow during exercise, the 
reliance on anaerobic metabolism may not be attenuated, and thus higher blood lactate 
accumulation will occur.  As noted at the outset, the proposed mechanisms by which 
nitrate/nitrite are reduced to NO involve reductase enzymes including xanthine 
oxidoreductase, however, it is not known if this action may is compromised in the milieu 
of skeletal muscle dysfunction present in PAH.  To further illuminate this suggestion, a 
logical next step would be to measure cGMP in tissue samples. An increase in cGMP 
would provide a more direct measure of NO bioavailability, and deliver greater 
mechanistic insight into the effect of supplementation on this pathway during exercise.  
Granted, as vasodilation in muscle is achieved via a variety of intrinsic and extrinsic 
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mechanisms (Sarelius & Pohl, 2010) altered NO metabolism as a result of nitrate 
supplementation may only provide part of the story, However, prior work connecting the 
two, specifically in terms of blood flow mediation (Casey et al., 2015; Ferguson et al., 
2013; Ferguson et al., 2016; Piknova et al., 2016), would suggest further work is 
warranted. 
Interestingly, previous findings have indicated a potential ‘fiber type’ effect of 
BRJ supplementation and subsequent exercise performance. This idea has originated 
from two separate lines of evidence, including the demonstration that blood flow and 
vascular conductance may be improved specifically in rat Type II muscle fibers after BRJ 
ingestion (Ferguson et al., 2013), and in humans, initial work indicates BRJ may be 
effective in improving shorter duration, high intensity efforts that would require Type II 
fiber recruitment (Coggan, Leibowitz, Kadkhodayan, et al., 2015; Coggan, Leibowitz, 
Spearie, et al., 2015; Rimer et al., 2016; Thompson et al., 2016; Wylie et al., 2016). We 
show that in rat muscle, nitrate/nitrite levels are higher in the soleus than vastus lateralis, 
which may be considered surprising as the former is almost entirely Type I in 
composition, and the latter Type II (Armstrong & Phelps, 1984). It has been postulated 
that neuronal NOS (NOS1, nNOS) is active primarily in type II fibers in the rat, and 
therefore exercises of higher intensity may lead to greater NO production via this well-
established pathway (Copp et al., 2013). Based on the findings herein, it could be 
hypothesized that the greater levels of nitrate/nitrite in Type I fibers may be a 
compensatory mechanism due to a reduced NOS1 function in oxidative muscle. Whether 
Type I fibers rely more heavily on other NO production mechanisms (such as the NO3--
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NO2--NO pathway) remains to be seen, but it may in part explain the discrepancy seen in 
muscle nitrate/nitrite levels reported here.  
 
Aim 3 
Hypothesis 3.1 – BRJ supplementation will result in a significant increase in 
exercise function through improved VO2max, strength and increased volitional running 
distance in both PAH and control rats, compared to those supplemented with placebo. 
 
As noted in Aim 1, exercise function was reduced in MCT rats. VO2max was 
significantly lower in both the BRJ and PL condition in MCT compared to CON 
(p=<0.01). There was a trend toward reduced grip strength in MCT under BRJ 
supplementation (p=0.08) and a decline in voluntary running performance in the PL trial 
(p=0.08) and to a lesser extent after BRJ gavage (p=0.12) when compared to CON. In a 
similar finding to Aim 2, repeated measures analysis determined BRJ had limited 
effectiveness in increasing exercise performance in MCT or CON rats in either pre-
injection or final testing. To the author’s knowledge, this is the first study to test the 
effectiveness of BRJ on maximal aerobic capacity and voluntary running in an animal 
model, and while supplementation did increase VO2max and time to exhaustion in 
absolute terms, this change was not robust enough to reach statistical significance. There 
has been significant work on dietary nitrate as an ergogenic aid in healthy individuals, 
athletes, and patient populations, with previous studies determined that acute dosing of 
BRJ reduced the oxygen cost of exercise at submaximal intensities (Bailey et al., 2009; 
Larsen et al., 2007; Vanhatalo et al., 2010). Mechanistically, it has been postulated that 
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lower oxygen cost of exercise (reduced ATP requirement at a given work output) may be 
a consequence of an improved aerobic metabolic efficiency, demonstrated via reduced 
intramuscular metabolites ADP and phosphate, as well as a sparing of muscle 
phosphocreatine during exercise post-supplementation (A. M. Jones, 2014a). 
Additionally, Larsen et al. (2011) reported improved mitochondrial function after three 
days of dietary nitrate supplementation, explained via reduced expression of adenine 
nucleotide translocase (ANT), which was subsequently correlated to recued VO2 
consumption during submaximal exercise. While we did not directly measures 
mitochondrial function, we did not see altered evidence of altered exercise metabolism 
(as measured via RER response at incremental workloads during submaximal exercise) 
post BRJ consumption in either MCT or CON rats. As such, a direct interrogation of 
mitochondrial function may elucidate an improved exercise economy in the PAH rat. 
With that said, there is evidence that mitochondrial function is altered in PAH (S. Y. 
Chan & Rubin, 2017; Piao, Marsboom, et al., 2010; Yu & Chan, 2017), therefore, the 
possibility of improved exercise economy via this mechanism is uncertain. Importantly, 
improved exercise economy should be considered distinct from exercise capacity. While 
a reduced VO2 at a given exercise intensity may theoretically increase submaximal 
exercise tolerance, there is equivocal evidence that nitrate supplementation improves 
exercise capacity. (A. M. Jones et al., 2018). Indeed, the effectiveness of BRJ in 
improving exercise performance in running/cycling tasks is variable, and seems to 
depend on the training status and dose-duration in healthy subjects (McMahon, Leveritt, 
& Pavey, 2017).  
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Improvements in exercise performance after an acute dose of BRJ have been 
shown, but not consistently. In a recent review Zafeiridis (2014) showed that exercise 
performance, measured via cycling and running time trials may be improved, however, 
the evidence that VO2max may be improved is limited. Indeed, one study showed that an 
acute dose of nitrate (via sodium nitrate in drinking water) reduced maximal oxygen 
consumption in trained cyclists (Bescos et al., 2011), further highlighting the 
inconsistency in results to date. What may be more important is a consideration of dietary 
nitrate and its potential ergogenic effects in clinical populations. Of greatest relevance to 
this study, BRJ has been shown to increase peak walking time and delay the onset of 
claudication in peripheral artery disease patients, representing a clinically relevant 
improvement in exercise performance (Kenjale et al., 2011). Interestingly, the 
improvement in walking performance was not associated with an increase in maximal 
aerobic capacity. It is postulated that in this instance, the demonstrated reduction in tissue 
deoxygenation may indicate increased muscle perfusion post BRJ supplementation, 
however, this was not measured directly. Similarly, dietary nitrate has been shown to 
improve aerobic exercise capacity in COPD patients (Berry et al., 2015), with a single 
dose of BRJ extending submaximal exercise time and reducing blood pressure compared 
to placebo. However the aforementioned inconsistency is highlighted by a more recent 
study indicating that 6 days of BRJ supplementation did not improve walking distance in 
the same condition, despite significant elevations in plasma nitrite levels (Friis et al., 
2017). Several studies have determined that dietary nitrate may be effective in improving 
exercise tolerance in left heart failure. A single dose of dietary nitrate was shown to 
increase VO2max and total work performed on a supine cycle exercise-test, despite no 
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improvement in exercise efficiency (Zamani et al., 2015). This is in slight contrast to the 
work of Eggebeen et al. (2016) who demonstrated that a single dose of BRJ was 
ineffective in increasing VO2max or submaximal cycling endurance in heart failure 
patients, but that a longer term (6 day) strategy was required to elicit positive changes in 
submaximal performance. However, the discrepancy in outcomes may have been due to 
dosage levels, which were higher in the previous study. Furthermore, it has been shown 
that dietary nitrate improves VO2peak and time to fatigue in heart failure patients with 
reduced ejection fraction (Coggan et al., 2018), and one study has considered the use of 
BRJ as an ergogenic aid in PAH. After 7 days of dietary nitrate consumption PAH 
patients tended to improve their power output at a given submaximal VO2, however, a 
significant difference was only observed in a sub-group of patients that were classed as 
dose ‘responders’. Additionally, VO2max and 6 minute walking distance were unaltered 
following supplementation (Henrohn et al., 2018). Initially, it would seem our results 
oppose those that have been demonstrated in patient populations, however, there are 
factors which must be taken into consideration when contextualizing our findings. Most 
notably, the predominant conclusion in aerobic exercise points to an improvement in 
submaximal exercise performance, however, we did not perform a steady-state 
submaximal test. As such, we were not able to determine the effectiveness of BRJ in 
augmenting performance from this perspective. Granted, voluntary wheel running is 
submaximal in activity, however, by definition it is carried out at a self-selected and 
variable pace. While it is possible to examine responses to exercise at submaximal 
intensities during a VO2max test, the fact that it is externally controlled and not subject to 
optimal self-pacing (as would usually be carried out during an endurance task), may limit 
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our ability to accurately assess true ‘performance’ parameters from a translational 
perspective (Noakes, 2008). However, the equivocal nature of findings in both healthy 
and patient populations to date adds weight to the idea that regardless of testing protocol, 
BRJ may have been ineffective at improving functional capacity in this model.  
The duration of BRJ dosing must also be taken into consideration. Of interest are 
the results of Eggebeen et al. (2016), who demonstrated a distinct difference in responses 
to exercise in HF patients, arguing that a longer nitrate intervention may be required to 
elicit mechanistic changes that account for improved performance. A. M. Jones et al. 
(2018) notes that acute dosing may be effective in improving exercise economy, but that 
greater doses (>8.5mmol) may be necessary to see changes in functional performance. 
Additionally, some of the potential mechanisms by which dietary nitrate may impact 
aerobic performance, including mitochondrial protein changes, blood flow modulation 
and calcium handling (A. M. Jones, 2014a), which may require a sustained dosing period 
to be sufficiently altered at the cellular level. Taken together, while we have not 
demonstrated a significant effect of an acute dose of BRJ on improving aerobic exercise 
function, this can be considered supportive of pervious work in this area. The 
inconsistencies outlined would suggest a need to optimize dosing strategies based on the 
outcome of interest. The findings have added to the body of literature, most notably by 
demonstrating a single dose of BRJ may not be sufficient to bring about changes in 
maximal exercise capacity or voluntary running distance in a PAH model. 
The work indicating dietary nitrate supplementation may target type II, fast twitch 
muscle fibers (Ferguson et al., 2013) led to the hypothesis that it may be efficacious in 
improving performance in higher intensity, short duration activities that would be 
  120    
considered ‘anaerobic’ in nature. This was a novel concept, primary because much of the 
rationale for using BRJ to improve performance centered on increasing NO with the 
downstream effect of increasing vasodilation leading to greater oxygen delivery to 
working muscle. However, such high intensity activity is less depended on oxygen 
availability to replenish ATP stores, and as such, would require interventions that directly 
modulate muscle contractile function. With that said, and increasing body of work has 
pointed to the benefits of dietary nitrate and anaerobic performance in healthy 
individuals, indicting the effectiveness of supplementation in improving repeated sprint 
performance, supramaximal cycling, and knee extensor power in healthy individuals 
(Aucouturier, Boissiere, Pawlak-Chaouch, Cuvelier, & Gamelin, 2015; Coggan, 
Leibowitz, Kadkhodayan, et al., 2015; Thompson et al., 2016; Wylie et al., 2016) and in 
clinical populations (Coggan, Leibowitz, Spearie, et al., 2015). The data in the present 
study would seem to contrast that found previously, in that we did not find an effect of 
BRJ in increasing grip strength in the PAH rat. However, as is the case in aerobic 
activity, results seem to be mediated by the duration of nitrate dosing. It may be that 
acute dosing improves contractile function via a direct effect on the sarcoplasmic 
reticulum and enhanced contractile sensitivity (Coggan & Peterson, 2018), however, we 
did not see this represented via improved force production. It has been argued that longer 
term supplementation may lead to protein changes in muscle contractile apparatus, 
resulting in improved force production (Hernandez et al., 2012), however, this idea has 
been challenged with evidence that in human muscle, an improvement in force post-BRJ 
ingestion is not related to changes in muscle protein expression (Whitfield et al., 2017). 
While the mechanisms of action are still under investigation, we may not have seen an 
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effect due to the nature of the grip-strength test. While it allows for the calculation of 
maximal force production, the test does not allow for rate of force production, and 
therefore measures of muscle power at various velocities, and an interrogation of these 
may lead to a more robust finding on the modulation of muscle contractile function in a 
PAH model.  
 
Conclusion 
We have shown that in a reliable pulmonary hypertensive animal model, blood 
flow is significantly reduced at rest, and to a greater extent, during moderate intensity 
exercise. These findings can be linked to previous work in this area, most notably that 
tissue oxygen supply and extraction are reduced in PAH patients. As such, a direct 
investigation of skeletal muscle blood flow, as carried out here, provides a novel 
description of peripheral maladaptations and exercise responses in the disease. It has also 
been shown that this reduced blood flow is not a result of capillary rarefaction at the 
skeletal muscle level, highlighting the potential importance of microcirculatory function 
as imperative in modulating blood flow. Importantly, a direct association between 
exercising blood flow and lactate accumulation was identified, adding a mechanistic 
explanation for the previously observed abnormal metabolic response to exercise in PAH.  
A link between exercising blood flow and traditional disease measures has also been 
highlighted, emphasizing the importance of exercise stress in understanding the 
adaptation to right heart functional and morphological changes that are central to PAH 
pathology.  
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Contrary to previous investigations, we did not see an effect of BRJ in 
augmenting exercising blood flow in either MCT or CON rats. Tendencies for improved 
flow at rest were seen in both groups, however, only in the rectus femoris muscle group 
were significant differences present. Findings herein did not show that BRJ mediated 
exercising blood flow either in health or disease. Interestingly, despite no improvements 
in blood flow, an acute dose of BRJ was sufficient to increase plasma nitrate and nitrite in 
caparison with longer term dosing strategies in both humans and animal models. A 
potential explanation for the limited effectiveness of dietary nitrate was proposed 
following the analysis of muscle nitrate and nitrite levels in both type I and type II muscle 
groups. We show that a primary type I muscle stores more nitrate/nitrite than type II, 
however, the lack of nitrite increases in muscle post-BRJ supplementation may indicate a 
compromised NO3--NO2--NO reduction pathway and therefore explain a lack of efficacy 
in dietary nitrate altering blood flow. Finally, acute dosing of BRJ did not significantly 
improve functional exercise capacity as measured by VO2max, voluntary wheel running, 
and grip strength. Given the equivocal nature of findings on dietary nitrate 
supplementation and exercise performance, this work adds to that body of knowledge by 
specifically testing its usefulness in a PAH model. Finally, results support the notion that 
an optimization of dosing strategies dependent on the desired outcome measures and 
patient characteristics may be required.  
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Limitations 
 The use of the monocrotaline model of pulmonary hypertension has limitations. 
While it has been employed as a model in PH research for decades, its validity as a 
representative pre-clinical model has been called into question. Most notably, the 
obstructive plexiform lesions found in the lungs of PAH patients do not seem to develop 
in this model (Gomez-Arroyo et al., 2012). As such, the mechanisms by which 
pulmonary pressures are altered and hemodynamic abnormalities arise may not be 
adequately replicated. Additionally, it has been shown that the induction of pulmonary 
hypertension via MCT may have systemic effects. This includes evidence of liver toxicity 
and lymphocytic myocarditis (Gomez-Arroyo et al., 2012; Stenmark et al., 2009), which 
are not consistently reported in PAH patients. Nevertheless, the RV hypertrophy and 
increased RV pressures are advantages that have resulted in the MCT model being a 
mainstay PH researchers, but as with all animal models, the extent to which they fully 
reflect disease pathophysiology in patients should be taken into consideration.  
 The acute dosing approach employed in this study was technically challenging, 
and also limited the amount of dietary nitrate that could be administered pre-exercise. 
Similar studies in rodents have traditionally involved the mixing of beetroot juice in 
drinking water over several days, with rats consuming the product ad libitum. While this 
is a methodologically simpler approach, the longer dosing strategy may allow for greater 
overall nitrate intake in the day(s) leading up to exercise. The gavage technique is limited 
by the amount of liquid that can be delivered at one time, hence our acute dose may have 
resulted in fewer mmol per kg body weight compared to previous investigations. For 
example, (Ferguson et al., 2013) reported a dose of 1mmol/kg/day in drinking water, 
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however, to achieve this dose via gavage would involve the administration of ~10ml of 
beetroot juice. Preliminary work determined rats could not consistently retain this amount 
of fluid via gavage, with instances of regurgitation common. Hence, we employed a 
lower dosing strategy of 0.5mmol/kg, which was more easily tolerated. With that said, we 
were able to achieve significant elevations in plasma nitrate/nitrite as previous groups 
using the longer term technique, highlighting at the very least, the gavage technique as 
suitable for increasing circulating nitrate/nitrite in treated animals. 
 Given the variability in blood flow measures, a within-rat design, as opposed to 
the between-rat comparison used here may have led to more conclusive findings. This 
would involve a more rigorous, and likely precarious methodology with each rat being 
gavaged twice and completing two run bouts following catheter placement surgery. 
Indeed, preliminary work indicated that both MCT and CON rats struggled to complete 
the second run bout when this approach was attempted. Another source of variability may 
lie in the florescent microsphere method itself. Blood flow quantification requires the 
adequate mixing of beads pre-injection, degradation of tissue, filtration, bead capture, the 
dissolving of dye and accurate pipetting before plate analysis. Each of these have the 
potential for microsphere (and therefore fluorescence) loss. Moreover, during bead 
injection, it is vital catheters are accurately placed in the aortic arch. If not, systemic flow 
may not be accurately captured. There were instances whereby blood flow data were 
compromised due to unequal left to right blood flow, and in such circumstances, the 
blood flow data was removed from subsequent analysis. However, continued work on 
optimizing the method proved useful in mitigating this problem.  
 
  125    
Future Directions 
 Undoubtedly, follow up studies should be carried out in other PAH models. Our 
lab has used the sugen-hypoxia and MCT-pneumonectomy models, both of which have 
been shown to produce a pulmonary hypertensive phenotype. Moreover, the sugen-
hypoxia model has been postulated as a more accurate model, with evidence that its 
mechanisms more closely related to heart and lung dysfunction seen in patient 
populations. With that said, the downstream effects, including that in skeletal muscle, 
require greater exploration, and investigating the blood flow response to exercise in this 
model would provide a fuller picture from a preclinical perspective. 
Further mechanistic analysis that may help explain the reduction in blood flow in 
PAH is warranted, particularly as this study suggested skeletal muscle capillary 
rarefaction may not be a determining factor. To rigorously assess this suggestion, a more 
thorough investigation of capillaization of skeletal muscle could be carried out. For 
example, a recent study measured capillarization via eATPase staining in rats that had 
undergone 12 weeks of wheel running (Beleza et al., 2019), and this alternative method 
of quantification may result in different findings. Moreover, interrogating known 
angiogenic and/or rarefactory pathways may elucidate the role of capillary changes at the 
muscle level. Potus et al. (2014) probed micro-RNAs and the VEGF pathway (a known 
mediator of angiogenesis) as a means of explaining the previously measured capillary 
rarefaction in muscle of PAH patients. Thus, measuring whole muscle protein via 
immunblotting, or alternatively, using RT-PCR to target relevant gene expression may be 
an appropriate next step in determining this activity in the MCT model. Lastly, the 
reduction in cardiac output and elevated respiratory muscle flow after MCT injection can 
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be connected to reduced peripheral perfusion, however, an interrogation into arterial 
function may highlight further maladaptations and potential therapeutic targets. As noted, 
in left heart failure there is evidence of arterial dysfunction leading to reduced blood 
flow, and future studies should attempt to understand how this may play a role in PAH.  
 The extent to which training might improve muscle blood flow should be 
investigated. Exercise has long been known as an angiogenic stimulus (Bloor, 2005), and 
given this description of reduced flow to skeletal muscle, pursuing this type of 
investigation would likely have significant translational value. Ideally, the identification 
of therapeutic targets should be followed up with interventions to address the problem, 
and given previous work (including in our lab) that exercise training has benefits specific 
to skeletal muscle, determining if blood flow improvements are possible would be a 
meaningful line of enquiry. Moreover, given the strong evidence that exercise training is 
beneficial in PAH, such a study would likely induce positive changes beyond those being 
interrogated at the skeletal muscle level.  
 Ultimately, the use of dietary nitrate in improving exercise tolerance in PAH 
patients should be investigated. While one study has begun this work, further exploration 
of potential ergogenic effects should be pursued. Specifically, the benefits demonstrated 
in left heart failure after BRJ supplementation, both in producing improvements in 
aerobic performance and strength/power would provide rationale for similar testing in 
PAH. To date, no study in patients has examined the effects of either acute or chronic 
dosing on strength and power parameters, which, given the clear deficiency reported in 
patients, merits further research. It is likely this work would involve the development of 
optimized dosing protocols, as has been suggested in healthy populations. The potential 
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benefits of using a readily available, non-pharmacological product to improve exercise 
performance would warrant a fuller investigation in this condition.  
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Appendices 
Appendix A: Dietary Nitrate Dose Response 
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Figure A5.1: Nitrate and nitrite dose responses 
 
Figure A5.1 represents plasma nitrate/nitrite responses to 3 different doses of dietary 
nitrate supplement, achieved via serial blood-draws at specific time-points post gavage 
(1mmol/kg – pink; 0.5mmol/kg – blue; 2mmol/kg – maroon, n=3). Greatest nitrate 
responses are seen between 2-3hrs post gavage, with a similar effect seen in nitrite at the 
0.5mmol/kg dosing level. At either 0.5 or 1mmol/kg, initial increases in nitrate and nitrite 
have returned to baseline at 24 hours. Both nitrate and nitrite remain elevated at 24hours 
at the highest dosing level.  
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Appendix B: Blood Flow Experiment Recording Sheet 
Rat number ________________    MCT / CON _________________ 
Rat weight _________________ 
Calculation for gavage dose: 
 
 
Calculation for microsphere number: 
 
 
Running intensity: 
 
 
Comments from Catheter placement surgery: 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
 
Description of blood flow experiment (Gary to complete): 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
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Tissue  Weight / Volume  
Ref blood 1                                ml 
Ref blood 2                                ml 
L. kidney                                g 
R. Kidney                                g 
Gast                                g 
RF                                g 
BF                                g 
EDL                                g 
TA                                g 
VL                                g 
Sol                                g 
Semi                                g                                
Diap                                 g 
 
Hemodynamics 
Time BP RVP Airway 
Pressure 
Temp Lactate Comments 
       
 
       
 
       
 
 
       
 
       
 
 
 
LV + S weight (g) _______ Right heart weight (g) _________ Fulton ______________ 
 
Tissues placed in box labeled 
______________________________________________________ 
 
Additional notes: 
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